
==== Front
Mol Med
Mol Med
Molecular Medicine
1076-1551
1528-3658
BioMed Central London

39227783
909
10.1186/s10020-024-00909-5
Review
Fetal origin of bronchopulmonary dysplasia: contribution of intrauterine inflammation
Yu Haoting
Li Danni
Zhao Xinyi
http://orcid.org/0009-0008-8118-2390
Fu Jianhua jianhuafu_sj@163.com

grid.412467.2 0000 0004 1806 3501 Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004 China
3 9 2024
3 9 2024
2024
30 13516 8 2023
23 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in infants and the most frequent adverse outcome of premature birth, despite major efforts to minimize injury. It is thought to result from aberrant repair response triggered by either prenatal or recurrent postnatal injury to the lungs during development. Intrauterine inflammation is an important risk factor for prenatal lung injury, which is also increasingly linked to BPD. However, the specific mechanisms remain unclear. This review summarizes clinical and animal research linking intrauterine inflammation to BPD. We assess how intrauterine inflammation affects lung alveolarization and vascular development. In addition, we discuss prenatal therapeutic strategies targeting intrauterine inflammation to prevent or treat BPD.

Keywords

Bronchopulmonary dysplasia
Intrauterine inflammation
Fetal inflammatory response
Chorioamnionitis
Alveolarization
Vascular development
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82071688 Fu Jianhua Key R&D Guidance Plan Projects in Liaoning Province2020JH1/10300001 Fu Jianhua issue-copyright-statement© The Feinstein Institute for Medical Research 2024
==== Body
pmcIntroduction

Bronchopulmonary dysplasia (BPD) is a multifactorial chronic lung disease and is a leading cause of morbidity and mortality in premature infants, particularly those with lower gestational age and birth weights (Jensen et al. 2021; Lui et al. 2019; Thébaud et al. 2019). During the past two to three decades, the incidence of BPD in preterm infants ranged from 11 to 50% in different countries, becoming increasingly prevalent because of the improved survival rates of extreme preterm births (Thébaud et al. 2019). BPD is characterized by respiratory distress and requires postnatal respiratory support, including mechanical ventilation (MV) and oxygen supplementation. Long-term sequelae of BPD, include neurodevelopmental and cognitive changes (Cheong et al. 2018), impaired lung function (Pérez-Tarazona et al. 2021), asthma (Sun et al. 2023), pulmonary vascular disease (Thébaud et al. 2019), cardiac dysfunction (Thébaud et al. 2019), and impaired immune development, causing recurrent infections and rehospitalizations (Duijts et al. 2020). “Classic” BPD first described by Northway et al. (1967), is characterized by fibrotic, scarred, and hyper-inflated lungs following MV and oxygen toxicity (Schmidt and Ramamoorthy 2022). It was initially described as a pulmonary disease affecting preterm infants with an oxygen requirement at 28 days of life (Day and Ryan 2017). Due to advancements in respiratory care, improved respiratory support techniques, and the introduction of surfactant therapy over the past fifty years, “classic” BPD has become less common (Allen and Panitch 2021). The term “new” BPD has been proposed recently and is characterized by impaired lung alveolarization and dysregulated vascularization. Specifically, it refers to reduced quantity and increased size of alveoli, structural simplicity and pulmonary microvascular dysplasia (Bancalari and Jain 2019).

BPD is affected by different prenatal and postnatal factors, including intrauterine inflammation, premature delivery, low birth weight, etc. Prenatal risk factors are strongly associated with the occurrence of BPD, regardless of advances in postnatal care (Kramer et al. 2009; Taglauer et al. 2018). BPD is typically initiated during pregnancy. Among the many factors contributing to BPD, inflammation plays a significant role in BPD onset, development, and severity (Higgins et al. 2018; Shahzad et al. 2016). Intrauterine inflammation can lead to rupture and premature delivery, which is the primary cause of BPD (Hwang and Rehan 2018). Intrauterine inflammation can also cause persistent lung inflammation in neonates, leading to developmental damage to the alveoli and pulmonary blood vessels (Dankhara et al. 2023; Salimi et al. 2022). The damage positively correlates with the severity of inflammation in the lungs and systemic organs (Choi et al. 2016). Intrauterine inflammation affects lung development through a variety of pathophysiological mechanisms. Clarifying prenatal intrauterine inflammation mechanisms is necessary to ensure the effective prevention and treatment of BPD. Therefore, we review recent evidence linking BPD development to intrauterine inflammation to investigate the fetal origin of BPD.

Methodology

A thorough search of PubMed’s literature was conducted to find articles related to bronchopulmonary dysplasia, intrauterine inflammation, prenatal inflammation, intrauterine infection, chorioamnionitis, fetal inflammatory response and other similar terms. Information from systematic reviews was prioritized while assessing the collected literature. We carried out a narrative review of the scientific literature, building on advances in laboratory science and clinical studies to present a current assessment of the contributions made by intrauterine inflammation to pathogenesis of BPD.

Exposure to intrauterine inflammation: definitions

Fetal intrauterine inflammation is commonly linked to chorioamnionitis, which is characterized by acutely inflamed placental membranes and chorions, usually caused by ascending microbial pathogens (Brosius Lutz et al. 2021). Histological changes include maternal chorioamnionitis, fetal funisitis, and chorionic vasculitis (Kim et al. 2015a; Muraskas et al. 2020). Microbial and inflammatory products in the amniotic fluid and choriodecidua activate the amnion and chorion, leading to neutrophil chemoattractant (CXCL-8/IL-8 and CSF3) release in an IL-1 and TNF-dependent manner (Cappelletti et al. 2020). The intra-amniotic inflammatory response, coordinated by chorion and amnion cells, fetal skin cells, and the umbilical cord, is mediated by toll-like receptor activation. This leads to pathogen-associated molecular patterns by the secretion of pro-inflammatory cytokines (Brosius Lutz et al. 2021). Chorioamnionitis is characterized by neutrophilic infiltration and inflammation at the maternal-fetal interface. There, it amplifies inflammation through interaction with other immune and resident cells (Cappelletti et al. 2020).

Chorioamnionitis often occurs in the placenta of premature infants, triggering an inflammatory cascade termed the maternal inflammatory response (MIR). Excessive neutrophil production of proteases, reactive oxygen species, and inflammatory cytokines during pathogenic clearance can accelerate fetal membrane aging, leading to rupture and preterm labor (Jain et al. 2022; Zhang et al. 2023a). Chorioamnionitis affects 36% of pregnancies shorter than 32 weeks and carries a substantial risk of extremely preterm birth (Dessardo et al. 2012). When chorioamnionitis spreads into the decidua and amniotic cavity, neutrophils infiltrate the chorioamnion and the levels of pro-inflammatory cytokines increase. Maternal neutrophils migrate from decidual vessels to fetal membranes, and fetal neutrophils migrate from fetal umbilical vessels to surrounding umbilical cord tissue in response to a cytokine gradient, constituting funisitis (Brosius Lutz et al. 2021). Funisitis and chorionic vasculitis, which are symptoms of fetal inflammatory response syndrome (FIRS), are caused by immune cells that invade the blood vessels and umbilical cord as inflammation intensifies (Martinelli et al. 2012; Murthy and Kennea 2007). Figure 1 provides a detailed illustration of several definitions around intrauterine inflammation as well as the relationship between maternal and fetal inflammatory responses.

Fig. 1 Chorioamnionitis and its relationships with maternal and fetal inflammatory response in intrauterine inflammation. The histology changes of chorioamnionitis include maternal chorioamnionitis, fetal funisitis and chorionic vasculitis. The infection invades the decidua and the amniotic cavity, leading to MIR and FIRS. Created with Biorender. com

FIRS, firstly characterized by Gomez et al. (1998), as a systemic inflammatory response with elevated fetal plasma interleukin 6 (IL-6) levels (> 11 pg/mL), is a subclinical condition characterized by fetal immune system activation. In 2002, Pacora et al. (2002) proposed funisitis and chorionic vasculitis as histological manifestations of FIRS, indicative of acute histological inflammation in the placenta, extraplacental membranes, and umbilical cords. 63.5% of the preterm infants have chorioamnionitis with FIR (Kovács et al. 2023). 8% of preterm newborns up to 33 weeks of age exhibit FIRS without MIR/FIR, accounting for 29% of all FIRS cases. Nomiyama et al. (2023) recommended testing IL-6 levels in umbilical cord blood to prevent missed FIRS diagnosis, and development of BPD and other morbidities. This applies to premature infants born to mothers with low risk of intra-amniotic inflammation (Nomiyama et al. 2023).

Relationship between intrauterine inflammation and BPD: recent evidence

Clinical evidence

Exposure to chorioamnionitis increases the risk of developing BPD in preterm infants, but does not influence the grade of BPD. A meta-analysis of 59 studies (1994–2009) involving 15,295 preterm infants found that chorioamnionitis exposure nearly doubled the odds of developing BPD (Hartling et al. 2012). Villamor-Martinez et al. (2019) presented an updated systematic review in 2019 that included 158 studies, 244,096 infants, and a wider range of covariates. They found that chorioamnionitis was a significant risk factor for BPD in preterm infants, regardless of the definition criteria for BPD. The impact of chorioamnionitis on BPD in their study may be modulated by its effect on gestational age and the risk of respiratory distress syndrome, but a significant link with BPD severity was not established (Villamor-Martinez et al. 2019).

The histological location and severity of intrauterine inflammation may influence its association with BPD (Kim et al. 2015b). Several studies have shown that BPD is more closely related to chorioamnionitis than to funisitis, suggesting lung inflammation directly contacting the airway epithelium may have a greater predisposition to BPD than systemic inflammation through the umbilical cord during the fetal period (Kim et al. 2015b; Villamor-Martinez et al. 2019). Histologically, both MIR and FIR can be classified into three stages and two grades, with necrotizing chorioamnionitis and necrotizing funisitis as the most severe stages respectively (Khong, et al. 2016). The incidence of BPD increased with the increased stage (or grade) of chorioamnionitis or funisitis (Costa, et al. 2023; Lee, et al. 2015b). This upward trend was thought to be related to earlier gestational age at delivery (Lee, et al. 2015b). Recently, Costa, et al. (2023) demonstrated that among extremely low gestational age neonates, exposure to stage 2–3 and grade 2 chorioamnionitis is an independent risk factor for the occurrence and severe form of BPD.

BPD arises from a complex interplay of pre-and/or postnatal factors, with adverse postnatal events complicating the association between intrauterine inflammation and BPD (Davidson and Berkelhamer 2017). For example, chorioamnionitis causes postnatal lung inflammation and subsequent lung injury in intubated infants, contributing to the development of BPD (Perniciaro et al. 2020). Moreover, preterm infants with respiratory distress syndrome and severe chorioamnionitis have an impaired surfactant response, which requires higher oxygen requirement and prolonged time to extubation after surfactant therapy, increasing BPD risk (Been et al. 2010).

FIRS is a risk factor for serious morbidity or mortality in newborns and is associated with an increased likelihood of unfavorable outcomes including BPD (Jung et al. 2020; Tang et al. 2021). Approximately 41.6% of newborns with gestational ages between 26 and 34 weeks exhibit FIRS (Francis et al. 2019). A systematic review and meta-analysis encompassing 10 articles and 1116 patients has shown that FIRS is linked to a higher frequency of BPD compared to neonates without FIRS (Tang et al. 2021). Furthermore, FIRS without MIR/FIR occurred in 8% of preterm births up to 33 weeks, accounting for 29% of FIRS cases. Recent study confirmed that neonates with FIRS but without MIR/FIR had the same elevated risk of BPD as neonates with FIRS and MIR/FIR (Nomiyama et al. 2023). Additionally, studies on FIR and BPD relationship indicate a significant increase in BPD odds among neonates with concurrent FIR, regardless of FIRS presence (Kovács et al. 2023).

Animal model evidence

Recent animal model-based studies have confirmed the link between intrauterine inflammation and BPD (Table 1). These models show that the induction of intrauterine inflammation using lipopolysaccharides (LPS) or endotoxin (ETX) during critical developmental phases of the lung may variably influence lung development in experimental animals (Abele et al. 2022; Cao et al. 2009; Mandell et al. 2021; Li et al. 2016; Pan et al. 2023; Tang et al. 2010; Ueda et al. 2006; Willems et al. 2017; Zhou et al. 2022). Rat alveolarization, occurring postnatally between days 4 and 21, mimics those of premature infants (O’Reilly and Thébaud 2014). Studies typically use rats exposed to inflammation during the lung development stage that resembles the human pseudoglandular stage (24–26 weeks of gestation) to model intrauterine infections (Mandell et al. 2021). Pregnant rats received intraperitoneal, intra-amniotic, or endocervical intramuscular injections of LPS (Cao et al. 2009), ETX (Abele et al. 2022), or Escherichia coli (E. coli) (Pan et al. 2018, 2023) to model prenatal inflammation. This leads to fetal rats with persistent aberrant development of alveoli and blood vessels throughout the infant period.

Table 1 Animal model evidences of the relations between intrauterine inflammation and BPD

Animal model	Agent for Intrauterine Inflammation	Time of induction	Time of pulmonary evaluation	Effects of intrauterine inflammation on lung	References	
WKAH/htm rats	1 µg/sac LPS	22.5 dGA (term: 22.5 dGA)	PN 3, 14, 60	Fewer and larger alveoli	Ueda et al. 2006	
Wistar rats	2.5 mg/kg LPS	20, 21 dGA (term: 22 dGA)	PN 2–14	Lung morphologically immature with fewer secondary septae and fewer and larger alveoli, reduced the rate of alveolarization	Cao et al. 2009	
Sprague-Dawley rats	10 µg/sac ETX

diluted in 50 µL NS

	20 dGA (term: 22 dGA)	PN 7, 14	Marked reduction in alveolarization and vascular growth, led to altered lung structure and pulmonary hypertension	Tang et al. 2010	
Sprague-Dawley rats	1 µg LPS (0.2 µg/µl )	16.5 dGA (term: 22 dGA)	PN 7	Alveolar simplification, as indicated by enlarged alveoli with decreased terminal airspace, decreased secondary septa and increased mean linear intercept	Li et al. 2016	
Merino ewes	10 mg/sac LPS

diluted in 50 µL NS

	87, 92 dGA (prematurely delivered at 9 dGA, term: 147 dGA)	PN 0	Pulmonary arteriolar remodeling	Willems et al. 2017	
Sprague-Dawley rats	10 µg ETX	20 dGA (term: 22 dGA)	PN 7, 14	Enlargement in parenchymal airspaces, a decrease in secondary septa, enlarged airspaces and decreased secondary septa	Mandell et al. 2021	
Sprague–Dawley rats	10 µg/sac ETXa

diluted in 50 µL NS

	20 dGA (term: 22 dGA)	PN 14	Sustained abnormalities of alveolar and vascular development, alters lung mechanics and causes right ventricular hypertrophy	Abele et al. 2022	
Sprague–Dawley rats	10 µg/sac LPS

diluted in 50 µL NS

	20.5 dGA (term: 22 dGA)	PN 1, 7, 14	Alveolar simplification and reduced secondary septa	Zhou et al. 2022	
Sprague–Dawley rats	E. coli suspension of 1MCF (2.5–3.5 × 108 CFU/mL)	15 dGA (term: 22 dGA)	PN 3, 7, 14, 17, 19, 21	Inflammatory infiltration, impaired alveolar vesicular structure, less alveolar numbers, and thickened alveolar septa	Pan et al. 2023	
a dGA, days of gestational age; PN, postnatal days; ETX, endotoxin; NS, normal saline; LPS, lipopolysaccharides; E. coli, Escherichia coli

Morphometric analyses, reveal that prenatal LPS exposure in animals lead to fewer and larger alveoli with less secondary septa, enlarged distal airspaces and a reduced peripheral vessels density (Abele et al. 2022; Cao et al. 2009; Zhou et al. 2022). These changes in the alveoli suggest an arrest in alveolarization, but not destruction closely resembling “new” BPD (Li et al. 2016). Observed systemic maternal inflammation on postnatal alveolarization is transient, with catch-up alveolar growth later (Cao et al. 2009). Extremely premature ovine lungs exhibit exacerbated inflammation and vascular abnormalities when continuously exposed to bacteria and bacterial ETX in utero (Willems et al. 2017). A significant decrease in alveolarization and vascular development changed the lung structure to resemble BPD traits in humans (Abele et al. 2022; Li et al. 2016; Tang et al. 2010).

Impacts of timing and duration of intrauterine inflammation exposure

Despite the potential link between intrauterine inflammation and BPD, multiple exposures to appropriate sequential intrauterine inflammation at varying times and durations may contribute to lung preconditioning and sensitization (Gussenhoven et al. 2017; Heymans et al. 2020; Kallapur et al. 2014). Studies indicate that intra-amniotic LPS exposure may shield premature lungs from additional inflammatory triggers by promoting immunological tolerance, reducing LPS-induced inhibition of alveolar and pulmonary vascular growth (Choi et al. 2016; Gisslen et al. 2014; Kunzmann et al. 2022; Kallapur et al. 2007; Kramer et al. 2005). Furthermore, a second intra-amniotic ETX injection suppressed monocyte function, including E. coli phagocytosis, hydrogen peroxide production, and IL-6 production (Kramer et al. 2005). Lambs repeatedly exposed to intra-amniotic LPS show lower expression of lung neutrophils, monocyte-inducible NO synthase, proinflammatory cytokine (IL-1β, IL-6, IL-8, and TNF-α), liver serum amyloid A3, TNF-α induced protein-3, etc. (Kunzmann et al. 2022; Kallapur et al. 2007). Moreover, lung remodelling similar to that observed in BPD occurred following single intra-amniotic LPS exposure. However, the inverse occurred after repeated intra-amniotic LPS exposure (Kallapur et al. 2005; Willet et al. 2000). These findings suggest that exposure to intra-amniotic LPS protects the lungs against BPD triggered by postnatal systemic inflammation.

Successive inflammatory exposure increases susceptibility to inflammatory responses, leading to exacerbation of the impact on pulmonary vascular development. In the study by Widowski et al. (2021), prenatal single inflammatory stimuli such as Ureaplasma or LPS inhibited the pro-angiogenic and vascular factors, including angiotensin (Ang)-1 and vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2). Previously exposure to Ureaplasma sensitized these indicators to an LPS-induced subsequent assault. Willems et al. (2017) demonstrated that chronic intra-amniotic Ureaplasma and subsequent LPS exposure promoted pulmonary inflammation, and reduced the expression of angiogenic growth factors and receptors compared to animals exposed to a single inflammatory event. In addition, a translational ovine model of intrauterine inflammation with successive exposure to Ureaplasma and LPS, negatively affected the epithelial stem/progenitor cell populations, resulting in reduced alveolar differentiation (Widowski et al. 2021).

Mechanisms of intrauterine inflammation-related BPD

We summarize the potential mechanisms by which intrauterine inflammation influences BPD etiology in terms of the impaired lung alveolarization (Fig. 2) and impaired pulmonary vascular development (Fig. 3).

Fig. 2 Potential mechanisms of intrauterine inflammation-related impaired lung alveolarization in BPD. The recruitment of macrophages, attenuated proliferation of ATII cells, abnormal directional migration of myofibroblasts, abnormal amount and crosslinking of extracellular matrix in the setting of intrauterine inflammation contribute to the arrested alveolar development in BPD, manifested by fewer and larger alveoli and fewer secondary septa. Created with Biorender. com

Fig. 3 Potential mechanisms of intrauterine inflammation-related impaired pulmonary vascular development in BPD. Both the alteration of endothelial cell-related angiogenic factors and enzymes, and the migration and maturation of dendritic cells in the setting of intrauterine inflammation contribute to the disordered microvascular in BPD. Created with Biorender. com

Impaired lung alveolarization

Recruitment of macrophages and persistent lung inflammation

Some chemokines or cytokines produced by intrauterine inflammation exposure could lead to recruitment of macrophages in fetal lungs (Cui et al. 2020; Jackson et al. 2022). Key chemokine systems in macrophage recruitment, such as the C-C chemokine ligand 2 (CCL2)–C-C chemokine receptor 2 (CCR2) pathway and CCL5–CCR5 pathway are involved in BPD development. Repetitive LPS exposure induces CCL2–CCR2 expression, leading to exudative macrophages and contributing to hypoalveolarization (Cui et al. 2020). CCR5, predominantly expressed on macrophages, promotes immune cells migration, leading to undesirable inflammatory side effects (Costa et al. 2016). Blocking CCR5 in an intra-amniotic LPS-induced rat model decreases macrophage aggregation and enhances alveolarization, thereby ameliorating the BPD phenotype. Elevated CCR5 levels promote the production of IL-1β (Chen et al. 2021), which, secreted by activated fetal lung macrophages, is the principal inflammatory mediator disrupting airway morphogenesis and triggering alveolar hypoplasia in BPD (Stouch et al. 2016). Increased levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine, are present in chorioamnionitis-affected amniotic fluid or fetal lungs exposed to ETX. A surge in prenatal GM-CSF might stimulate an increase in the number of macrophages in the developing fetal lung. When subjected to a second exposure, such as hyperoxia, these accumulated interstitial macrophages are released into the alveolar space during postnatal life (Cheah et al. 2021b).

The recruitment of macrophages leads to a further imbalance between pro- and anti-inflammatory factors, which is another characteristic of BPD (Heydarian et al. 2022). Recent studies show that in BPD models, inflammation induced-classically activated/(M1) phenotype is aggravated, while alternatively activated/(M2) phenotype in macrophages is suppressed (Arora et al. 2018; Hirani et al. 2022; Syed and Bhandari 2013). Elevated macrophages levels produce neutrophil chemoattractant, inducing neutrophil migration out of pulmonary capillaries into the air space, resulting in continual lung inflammation (Kalymbetova et al. 2018; Xia et al. 2015). The inflammatory alveolar microenvironment reduces the survival of alveolar type II (ATII) cells while promoting matrix remodelling and activating fibroblasts (Hirani et al. 2022). Macrophages also contribute to pulmonary differentiation arrest by influencing the epithelial–mesenchymal transition process in ATII cells, likely being regulators of arrested alveolarization in BPD (Zhu et al. 2023).

Attenuated proliferation of ATII cells

ATII cell populations decreased after intrauterine inflammation exposure, leading to impaired function restoration of alveolar epithelium morphology. In an intra-amniotic LPS injection model, LPS induces the phosphatase and tensin homolog, hindering ATK phosphorylation and ATII cell proliferation (Zhou et al. 2022). Normal lung growth and homeostasis depend on epithelial–mesenchymal interactions, which are mediated by the parathyroid hormone-related protein. LPS causes failure of the parathyroid hormone-related protein-driven epithelial-mesenchymal paracrine loop in the lung explants of rat fetuses. It therefore alters the effect of interstitial lipofibroblasts on ATII cells proliferation (Rehan et al. 2007). Furthermore, intra-amniotic LPS exposure in a lamb model resulted in a decrease in ATII cells after prenatal inflammation (Widowski et al. 2021). The ATII cells are stem cells responsible for homeostasis and regeneration in the alveolar compartments (Wu and Song 2020). Fiaturi et al. (2018) demonstrated the trans-differentiation of ATII cells into ATI cells. Once the number and function of ATII cells are compromised, ATII cells cannot rapidly proliferate and differentiate into ATI cells, compromising maintenance of alveolar homeostasis (Marega et al. 2023).

Abnormal directional migration of myofibroblasts

Alveolar myofibroblasts, important for alveolar maturation, initiate a process called secondary septation during alveolar formation. Alveolar myofibroblasts are believed to migrate into the septal tips and lengthen secondary septa during alveolarization (Li and Gong 2020; Li et al. 2012). Intra-amniotic injection of LPS increases the migration speed, disrupts directional persistence, and causes an abnormal distribution of myofibroblasts in neonatal rat lungs. This leads to alveolarization arrest, which is a pathogenic mechanism of BPD (Li and Gong 2020; Li et al. 2012; Li et al. 2016). The actin cytoskeleton and cell migration in different cell types are significantly regulated by the epidermal growth factor receptor (EGFR) (Li et al. 2016). Intra-amniotic LPS exposure can activate EGFR by disrupting the asymmetric localization of phospho-EGFR (Li et al. 2012), leading to RhoA/Rho kinase activation and disruption of the directional migration of myofibroblasts (Li et al. 2016). In this process, EGFR phosphorylation is mediated by Src, which can be inhibited by the COOH-terminal Src kinase, suggesting that the COOH-terminal Src kinase/Src/EGFR signaling pathway may play a crucial role in modulating myofibroblast migration in a particular direction (Li et al. 2016). The 14-3-3β protein is also closely related to cytoskeletal remodelling and cell migration. LPS cannot activate RhoA or disturb myofibroblast polarization when 14-3-3β is knocked out, suggesting that 14-3-3β is required for RhoA activation by EGFR (Li and Gong 2020).

Transforming growth factor-α (TGF-α), a ligand of EGFR, has been proposed as the primary stimulus for maintaining myofibroblast polarity. This may contribute to arrested alveolar development in BPD. LPS treatment regulates EGFR activation by modulating TGF-α (Li and Gong 2020; Li et al. 2012). According to an earlier study, overexpression in the lungs disrupts postnatal alveolarization (Kramer et al. 2007). Moreover, intra-amniotic LPS exposure in a rat model led to the suppression of histone deacetylases 2 expression and activity, which induced TGF-α expression and disrupted alveolar morphology (Ni et al. 2014). Similar to TGF-α, LPS activated Src regulates cell surface metalloproteinase tumor necrosis factor-α converting enzyme (TACE) activity, leading to the cleavage of membrane-bound EGFR proligands, allowing them to attach to EGFR and activate downstream kinases (Li et al. 2016). Moreover, LPS-treated fetal mouse lung explants inhibit fibroblast growth factor-10 (FGF-10) expression by activating toll-like receptor 2 (TLR2) or TLR4.Consequently disrupted normal positioning of myofibroblasts around the saccular airways and abnormal saccular airway morphogenesis occurs (Benjamin et al. 2007).

Abnormal amount and crosslinking of extracellular matrix (ECM)

The lung ECM consist of collagens, elastin, glycoproteins, and proteoglycans, providing structural scaffolding and biochemical support to tissues and cells (Liu et al. 2021; Mižíková and Morty 2015). Intrauterine inflammation may cause abnormal ECM composition, disorganized elastin and collagen fibers, and abnormal ECM crosslinking, contributing to arrested alveolarization in BPD (Mižíková et al. 2015; Rippa et al. 2021).

Elastic fiber formation in the respiratory region of the lungs is important for alveolar formation. Exposure to intrauterine inflammation disrupts elastic fiber organization and decreases elastin assembly components without redepositing elastin fibers or changing total lung elastin content (Benjamin et al. 2016; Hanita et al. 2017). Benjamin et al. (2016) showed that LPS could activate the NF-κB pathway through TLR4 while inhibiting the expression of Fbln5 in lung fibroblasts, resulting in dysfunctional elastic fiber network formation. Another study, using preterm lambs in an ovine model with intrauterine inflammation observed no tissue destruction, elastin fragmentation, or thick deposits of elastin. However, necrotizing funisitis resulted in a decreased volume density of the secondary septal crests. The same study suggested that the alveolar emphysema, a histological feature of “new” BPD, results from inhibited alveolarization (Hanita et al. 2017).

Collagens are highly abundant proteins in the ECM that provide resistance and support to tissues (Mižíková and Morty 2015). They have been shown to increase production in intrauterine inflammation-induced BPD animal models (Chou et al. 2016). Increased collagen area fraction was also observed in lung sections of patients with BPD (Ruschkowski et al. 2022). In a rat model of intrauterine inflammation, type I collagen expression significantly increased on embryonic day 21 and postnatal days 1, 3, 7, and 14, leading to abnormal lung development, with fewer alveoli and thickened alveolar septa in fetal and neonatal rats (Pan et al. 2018).

In the ECM, fibronectin, a high-molecular-weight glycoprotein, binds to cells through integrins that control migration and differentiation. Insufficient fibronectin levels may impede alveolar formation in premature lungs (Jin et al. 2020). In BPD, fibronectin, is suppressed and abnormally localized affecting airway proliferation and lung tissues (Benjamin et al. 2009; Jin et al. 2020; Prince et al. 2005). LPS actives NF-κB through functional TLR4, altering mesenchymal fibronectin expression. This interferes with interactions between epithelial and mesenchymal cells, as well as prevents distal airway branching and alveolarization (Prince et al. 2005). Jin et al. (2020) indicated that perinatal exposure to LPS in a mouse model of BPD caused the release of IL-33 from epithelial cells via myeloid differentiation factor 88, protein 38, and NF-κB protein 65. Elevated IL-33 in BPD triggered neutrophil extracellular trap formation via its receptor ST2, which degraded fibronectin in alveolar epithelial cells (Jin et al. 2020). LPS may also inhibit the fibronectin receptor integrin α8β1, resulting in a reduction of mesenchymal cell adhesion and migration (Benjamin et al. 2009).

Matrix metalloproteinases (MMPs), proteinases that participate in ECM degradation, are activated in inflamed tissue and inhibited by tissue inhibitors of matrix metalloproteinases (TIMPs) (Mižíková and Morty 2015; Zhou et al. 2018). Inflammatory responses mediated by IL-6, IL-1β, and tumor necrosis factor-α stimulate the secretion of MMPs (Goldenberg et al. 2008). The imbalance of MMPs and TIMPs may participate in the early inflammatory phase of BPD by regulating ECM remodelling. Yan et al. (2020) reported upregulated MMP-9 and TIMP-1 levels and MMP-9/TIMP-1 ratios in umbilical cord blood, considered predictive indicators of FIRS. MMP-9, TIMP-1, and MMP-9/TIMP-1 ratios in cord blood are closely correlated with the occurrence of BPD (Fukunaga et al. 2009). However, Lee et al. (2015a) reported that low TIMP-2 serum levels at birth may be associated with the subsequent development of BPD, and no significant differences were observed in MMP-8, MMP-9, or TIMP-1 levels. Therefore, different subsets of MMPs and TIMPs may play different roles in FIRS and BPD, which requires further evaluation.

TGF-β, a multifunctional polypeptide cytokine, is mainly secreted and stored in the ECM as a latent complex (Minton et al. 2014). TGF-β signaling activation in lung mesenchymal stromal cells enhance ECM deposition, inhibit branching morphogenesis and alveolarization, thereby promoting the progression of BPD (Aly et al. 2019; Chanda et al. 2019; Chen et al. 2011). Intra-amniotic ETX or LPS exposure increases lung TGF-β1 levels and induces the phosphorylation and translocation of the intracellular effectors of Smad2 to the nucleus (Collins et al. 2013; Kunzmann et al. 2007). Moreover, the expression of Cav-1, a structural component of caveolae that facilitates the degradation of TGF-β receptors, decreases after LPS exposure (Collins et al. 2013). The connective tissue growth factor (CTGF) is a downstream mediator of TGF-β1 that mediates the profibrotic effects of TGF-β1 by promoting fibroblast growth and ECM synthesis (Chen et al. 2011; Kunzmann et al. 2007). Increased CTGF levels contribute to fibrosis and pathogenesis of BPD after intra-amniotic LPS exposure (Collins et al. 2013). However, another study reported decreased concentration of CTGF in BPD led to microvasculature injury and alveologenesis, which is more consistent with the pathological changes associated with “new” BPD (Kunzmann et al. 2007).

Impaired pulmonary vascular development

Alteration of endothelial cell-related angiogenic factors and enzymes

Disordered microvascular development is another hallmark of BPD pathogenesis. The angiogenic factor VEGF is the most potent activator of angiogenesis and promotes the migration, proliferation, and differentiation of endothelial cells in existing vessels, thereby generating and maintaining new blood vessels (Lazarus and Keshet 2011; Laddha and Kulkarni 2019). Early VEGF-related intrauterine inflammation disrupts crucial growth factor signaling, which can lead to aberrant lung development and exacerbate BPD (Abman 2010). Damage during the pseudoglandular stage has been linked to markedly reduced VEGF expression in the lung tissue of fetal and neonatal rats (Pan et al. 2018). Decreased VEGFR expression has also been observed in a rat model of chorioamnionitis-induced BPD (Somashekar et al. 2016). Moreover, the treatment of newborn rats with a VEGFR inhibitor impairs pulmonary vascular growth and initiates pulmonary hypertension. These effects are long term and last well into adulthood (Le Cras et al. 2002). Besides the VEGF pathway, an early study showed that intra-amniotic LPS stimulates angiogenesis, migration, and proliferation in pulmonary cells, by inducing chemokines MIP-1α and MCP-1, leading to aberrant vascular development. The increased angiogenesis may expand the area between air spaces and capillaries and potentially creating a barrier to gas exchange, which is similar to aberrant alveolar capillaries in the BPD affected lungs (Miller et al. 2010).

Endothelial nitric oxide synthase (eNOS) crucial for angiogenesis and lung development, shows decreased activity in BPD models (Hirsch et al. 2020). Moreover, soluble endoglin is increased in the amniotic fluid of women with chorioamnionitis. Somashekar et al. (2016) showed that intrauterine exposure to an adenovirus overexpressing soluble endoglin decreased lung eNOS expression and phosphorylated Smad1/5 in rat pups. Simultaneously, a decrease in lung vascular density, increased pulmonary vascular remodelling, and increased medial wall thickness was observed. Angiotensin converting enzyme (ACE) is located mainly on the luminal surface of pulmonary endothelial cells and may be implicated in lung development. ACE is present in the human fetal lung at as early as 12 weeks of gestation, and its expression is downregulated in BPD lungs (Castro et al. 2014). ACE1 and ACE2 activities within the lungs counterbalance each other, with their ratio (ACE1/ACE2) correlating to the degree of lung injury (Wösten-van Asperen et al. 2011). Hillman et al. (2014) reported that exposure to intra-amniotic LPS or Ureaplasma parvum decreases ACE1 and increases ACE2, altering the ACE1/ACE2 ratio four-fold. This suggests that exposure to intrauterine inflammation-induced alterations in ACE may contribute to the development of BPD.

Migration and maturation of dendritic cells

Dendritic cells, essential for normal postcanalicular lung development, may contribute to dysangiogenesis associated with BPD. Prenatal exposure to microorganisms may accelerate the migration and maturation of dendritic cells in the lungs of preterm infants. De Paepe et al. (2011) reported a more than three-fold increase in dendritic cells in the lungs of early control infants with a history of chorioamnionitis/prenatal infection. Thus, massive recruitment of dendritic cells to the lungs may be linked to the pathogenesis of BPD, possibly because of their ability to modulate angiogenesis (De Paepe et al. 2011).

Prenatal treatment and prevention of intrauterine inflammation-related BPD

As the important role of intrauterine inflammation in BPD became understood, several potential prenatal treatment and prevention strategies on BPD were proposed, keeping animal model evidence in consideration (Fig. 4). While some of these strategies have been clinical utilized, there is currently insufficient data to assess their effectiveness in addressing intrauterine inflammation-related BPD.

Fig. 4 Prenatal treatment and prevention of intrauterine inflammation-related BPD. Corticosteroids, vitamin D, IL-1Ra, anti-sFlt-1 monoclonal antibody, prolyl-hydroxylase inhibitor drugs and mesenchymal stem (stromal) cells were proposed to be the prenatal treatment and prevention strategies based on the mechanisms of intrauterine inflammation-related BPD. Created with Biorender. com

Corticosteroids

Prenatal corticosteroids, a standard treatment for pregnancies at risk of preterm delivery between 24 and 34 weeks, have been used clinically for decades (Jobe and Goldenberg 2018). As potent anti-inflammatory agents, corticosteroids can suppress the inflammatory effects of intrauterine infections on the fetus, decreasing the risk of mortality and morbidity in preterm newborns (Conde-Agudelo et al. 2020; Ninan et al. 2022). A meta-analysis of seven observational studies suggested prenatal corticosteroids may effectively reduce adverse neonatal outcomes (e.g. neonatal mortality, respiratory distress syndrome, patent ductus arteriosus, intraventricular hemorrhage) caused by histological chorioamnionitis (Been et al. 2011).

While clinical research on the effects of prenatal corticosteroids in infants with BPD remain limited, animal models suggest great potential impact. Those studies have shown that LPS and corticosteroid-mediated molecules interact in the developing lungs, affecting the prenatal LPS-induced intrauterine inflammation model. In an ovine intrauterine inflammation model, maternal intramuscular injection of betamethasone (0.5 mg/kg) before delivery counteracted LPS-induced TGF-β pathway activation. Moreover, caveolin-1, which enhances TGF-β receptor degradation, was increased. Betamethasone treatment seven days before exposure to LPS prevented an increase in the downstream TGF-β signaling CTGF levels (Collins et al. 2013). Significantly, the effect of prenatal corticosteroids on intrauterine inflammation-related BPD varies according to the timing of administration. Kuypers et al. (2012) indicated that lung inflammation is modulated by the exposure time to corticosteroids, which are related to pro-inflammatory stimuli. Their study demonstrated that betamethasone treatment administered seven days after intra-amniotic LPS failed to diminish lung inflammation and instead accelerated lung maturation. However, lung inflammation was relieved and lung maturation was more restrained when betamethasone was applied seven days prior to intra-amniotic LPS (Kuypers et al. 2012).

The use of corticosteroids is controversial due to their immunosuppressive effects, which may raise the risk of neonatal infection and/or exacerbate systemic infections of mother (Conde-Agudelo et al. 2020). However, the results of the meta-analysis of the effects of prenatal corticosteroids in preterm labor, with clinical or histological chorioamnionitis showed that there was no significantly increased risk (Been et al. 2011). Another Cochrane review showed that, for the pregnant women, prenatal corticosteroids therapy does not raise the risk of endometritis, puerperal sepsis, or chorioamnionitis (Roberts et al. 2017). In brief, randomized controlled trials evaluating the efficacy of prenatal corticosteroids on preventing intrauterine inflammation-related BPD are relatively safe and expected.

Vitamin D

Vitamin D is a sterol hormone with anti-inflammatory properties that modulates normal fetal lung development (Mandell et al. 2015). Vitamin D deficiency has been reported in 70% of preterm infants (Park et al. 2020). According to a meta-analysis that included 909 infants, prenatal vitamin D deficiency and low vitamin D levels are associated with neonatal BPD (Park et al. 2020). Early vitamin D supplementation could thus significantly reduce inflammatory response thereby preventing and reducing BPD incidence in preterm infants (Ge et al. 2022). Mandell et al. (2014) reported that intra-amniotic vitamin D injection treatment at 14 days in fetal rats improved alveolar and vascular growth by 45% and 25%, respectively. In addition, vitamin D enhanced fetal ATII cell growth in the presence of ETX-induced growth suppression by 73%, suggesting that the effect of prenatal vitamin D therapy may be partially explained by its direct influence on alveolar and vessel growth (Mandell et al. 2014). Another study demonstrated that vitamin D administration alleviates prenatal inflammatory damage by inhibiting the synthesis of IFN-γ. Liu et al. (2018) discovered that infants whose mothers had mid-pregnancy vitamin D concentrations of ≥ 30 ng/mL had considerably lower levels of IFN-γ. It is therefore reasonable to infer that IFN-γ may be a key factor in the involvement of vitamin D deficiency in intrauterine inflammation-related BPD. Specifically, vitamin D boosts the methylation of vitamin D response elements in the IFN-γ-promoter region and inhibits the LPS-induced expression of IFN-γ production in CD8+ T cells, leading to enhanced maturation of alveoli in an intra-amniotic LPS-induced BPD rat model (Liu et al. 2018). The effect of prenatal vitamin D supplementation on intrauterine inflammation-related BPD is promising, however, more mechanism studies and clinical trial evidence are needed.

Other biologics: IL-1Ra, anti-sflt-1 monoclonal antibody, and prolyl-hydroxylase inhibitor drugs

IL-1 is a central inflammatory cytokine present in the chorioamniotic fluid and lung effluent of preterm infants after birth (Stouch et al. 2016). Studies have demonstrated that prophylactic administration of an IL-1 receptor antagonist (IL-1Ra) almost completely protects against BPD and permits almost normal lung development in mouse models with clinical relevance (Nold et al. 2013). A similar observation in an ovine model proved that IL-1Ra reduced fetal pulmonary and systemic inflammatory responses to intra-amniotic LPS (Kallapur et al. 2009). While the therapeutic effect of IL-1Ra on BPD remain unproven, the favorable safety profile of IL-1Ra is well established by a cohort study. Including 26 patients ages 0.80–42.17 years who were treated with IL-1Ra for at least 36 months, this study created a substantial track record for the safety of this treatment (Sibley et al. 2012). Soluble fms-like tyrosine kinase1 (sFlt-1) is an endogenous antagonist of VEGF that inhibits VEGF activity by directly interacting with free VEGF protein. These results in decreased downstream activation of membrane-associated VEGF receptors. Significantly, prenatal anti-sFlt-1 monoclonal antibody therapy preserved lung alveolar and vascular growth in an intrauterine inflammation model of BPD. It also reduced the adverse lung effects of intra-amniotic ETX (Wallace et al. 2018). Hypoxia-inducible factors (HIF), which are potent upstream regulators of diverse signaling pathways, also play an important role in supporting normal lung development (Semenza 2019). HIF signaling can be strengthened through pharmacological therapy with prolyl-hydroxylase inhibitor drugs that stabilize HIF. Prenatal selective prolyl-hydroxylase inhibitor drugs, such as dimethyloxalylglycine or GSK360A, increase the lung protein content of both HIF isomers, HIF-1α and HIF-2α, as well as VEGF and eNOS. They also preserve lung growth and function following prenatal ETX exposure, thereby preventing pulmonary hypertension in a rat model of chorioamnionitis-induced BPD (Hirsch et al. 2020). However, the clinical application of anti-sFlt-1 monoclonal antibody and prolyl-hydroxylase inhibitors, especially for pregnant women in the late stages of pregnancy, still requires more evaluation.

Mesenchymal stem (stromal) cells

Mesenchymal stem (stromal) cells, originating from embryonic splanchnic mesoderm, shows their importance by differentiating into various lung cells (Zhang et al. 2023b). It can coordinate key processes in lung morphogenesis by differentiating into either alveolar and vascular cells, or into fibroblasts and smooth muscle cells, which are crucial in the pathogenesis of BPD (Aly et al. 2019). The preventive effect of mesenchymal stem (stromal) cells against BPD in animal models appears to be mediated by secreted extracellular vesicles (Abele et al. 2022). Significantly, prenatal extracellular vesicle treatment significantly reduced the expression of inflammasome gene signals NLRP-3 and IL-1β in a chorioamnionitis-induced BPD model, whilst enhancing distal lung branching. It also preserved normal lung angiogenesis and vascular growth by increasing VEGF expression (Abele et al. 2022). Specifically, microvesicles, a type of extracellular vesicle that originate from cell membranes, enhance lung morphology and development, reduce lung fibrosis, repair peripheral pulmonary blood vessel loss, and mitigate pulmonary vascular remodelling. This assists normal lung development and their action is possibly associated with modulation of lung macrophage phenotype (Willis et al. 2018). In an intrauterine LPS-induced BPD model, microvesicle treatment on postnatal day seven improved alveolarization by promoting the proliferation of AT2 cells, which may be mediated by inhibition of the phosphatase and tensin homolog/AKT pathway. Microvesicle treatment also attenuates lung inflammation caused by prenatal LPS exposure by suppressing phospho-protein 38, phospho-JNK, and phospho-ERK expression (Zhou et al. 2022). Therefore, extracellular vesicle treatment may be a novel therapeutic strategy for the prevention of BPD caused by prenatal inflammation. Clinical trials show the promise of mesenchymal stem (stromal) cells therapy in preventing and treating BPD in early preterm infants (Yilmaz et al. 2021; Wu et al. 2020). Further clinical trials are required to demonstrate the efficacy and safety of prenatal mesenchymal stem (stromal) cells therapy for BPD, even if preclinical studies have confirmed its significance.

Conclusion

In summary, targeting inflammation within the womb is the critical step in preventing bronchopulmonary dysplasia, a condition that disrupts healthy lung development in premature infants. Several promising prenatal therapeutic strategies have been introduced, yet future challenges include identifying ways to better predict BPD based on evidence of prenatal inflammation and developing innovative and preventive management strategies for BPD.

Acknowledgements

Not applicable.

Author contributions

HTY and DNL performed literature reviewing and prepared the original draft of the manuscript. XYZ prepared the figures. HTY and JHF conceptualized the writing and edited the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by grants from the National Natural Science Foundation of China (number 82071688) and the Key R&D Guidance Plan Projects in Liaoning Province (2020JH1/10300001).

Data availability

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

ACE Angiotensin converting enzyme

ATI Alveolar type I

ATII Alveolar type II

BPD Bronchopulmonary dysplasia

CCL2 C-C chemokine ligand 2

CCR2 C-C chemokine receptor 2

CTGF Connective tissue growth factor

ECM Extracellular matrix

EGFR Epidermal growth factor receptor

eNOS Endothelial nitric oxide synthase

ETX Endotoxin

FGF-10 Fibroblast growth factor-10

FIR Fetal inflammatory response

FIRS Fetal inflammatory response syndrome

GM-CSF Granulocyte-macrophage colony-stimulating factor

HIF Hypoxia-inducible factors

IL-1Ra IL-1 receptor antagonist

IL-6 Interleukin 6

LPS Lipopolysaccharides

MIR Maternal inflammatory response

MMPs Matrix metalloproteinases

MV Mechanical ventilation

sFlt-1 Soluble fms-like tyrosine kinase1

TACE Tumor necrosis factor-α converting enzyme

TGF-α Transforming growth factor-α

TIMPs Tissue inhibitors of matrix metalloproteinases

TLR2 Toll-like receptor 2

VEGF Vascular endothelial growth factor

VEGFR-2 Vascular endothelial growth factor receptor-2

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

Abele AN Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis Am J Physiol Lung Cell Mol Physiol 2022 322 2 L179 90 10.1152/ajplung.00329.2021 34878940
Abele AN, et al. Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis. Am J Physiol Lung Cell Mol Physiol. 2022;322(2):L179–90.34878940 10.1152/ajplung.00329.2021
Abman SH Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease Adv Exp Med Biol 2010 661 323 35 10.1007/978-1-60761-500-2_21 20204740
Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol. 2010;661:323–35.20204740 10.1007/978-1-60761-500-2_21
Allen J Panitch H Bronchopulmonary dysplasia-A historical perspective Pediatr Pulmonol 2021 56 11 3478 89 10.1002/ppul.25341 33638603
Allen J, Panitch H. Bronchopulmonary dysplasia-A historical perspective. Pediatr Pulmonol. 2021;56(11):3478–89.33638603 10.1002/ppul.25341
Aly H Mansi Y Ez El Din Z Gabr Metwally H Sabry A Mesenchymal stromal cells and TGF-β1 in tracheal aspirate of premature infants: early predictors for bronchopulmonary dysplasia? J Perinat Med 2019 47 4 470 7 10.1515/jpm-2018-0305 30789824
Aly H, Mansi Y, Ez El Din Z, Gabr Metwally H, Sabry A. Mesenchymal stromal cells and TGF-β1 in tracheal aspirate of premature infants: early predictors for bronchopulmonary dysplasia? J Perinat Med. 2019;47(4):470–7.30789824 10.1515/jpm-2018-0305
Arora S Dev K Agarwal B Das P Syed MA Macrophages: their role, activation and polarization in pulmonary diseases Immunobiology 2018 223 4–5 383 96 10.1016/j.imbio.2017.11.001 29146235
Arora S, Dev K, Agarwal B, Das P, Syed MA. Macrophages: their role, activation and polarization in pulmonary diseases. Immunobiology. 2018;223(4–5):383–96.29146235 10.1016/j.imbio.2017.11.001
Bancalari E Jain D Bronchopulmonary dysplasia: 50 years after the original description Neonatology 2019 115 4 384 91 10.1159/000497422 30974430
Bancalari E, Jain D. Bronchopulmonary dysplasia: 50 years after the original description. Neonatology. 2019;115(4):384–91.30974430 10.1159/000497422
Been JV Rours IG Kornelisse RF Jonkers F de Krijger RR Zimmermann LJ Chorioamnionitis alters the response to surfactant in preterm infants J Pediatr 2010 156 1 10 e51 10.1016/j.jpeds.2009.07.044 19833352
Been JV, Rours IG, Kornelisse RF, Jonkers F, de Krijger RR, Zimmermann LJ. Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr. 2010;156(1):10–e51.19833352 10.1016/j.jpeds.2009.07.044
Been JV Degraeuwe PL Kramer BW Zimmermann LJ Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis BJOG 2011 118 2 113 22 10.1111/j.1471-0528.2010.02751.x 21054759
Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJ. Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis. BJOG. 2011;118(2):113–22.21054759 10.1111/j.1471-0528.2010.02751.x
Benjamin JT Smith RJ Halloran BA Day TJ Kelly DR Prince LS FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by toll-like receptor activation Am J Physiol Lung Cell Mol Physiol 2007 292 2 L550 8 10.1152/ajplung.00329.2006 17071719
Benjamin JT, Smith RJ, Halloran BA, Day TJ, Kelly DR, Prince LS. FGF-10 is decreased in bronchopulmonary dysplasia and suppressed by toll-like receptor activation. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L550–8.17071719 10.1152/ajplung.00329.2006
Benjamin JT Gaston DC Halloran BA Schnapp LM Zent R Prince LS The role of integrin alpha8beta1 in fetal lung morphogenesis and injury Dev Biol 2009 335 2 407 17 10.1016/j.ydbio.2009.09.021 19769957
Benjamin JT, Gaston DC, Halloran BA, Schnapp LM, Zent R, Prince LS. The role of integrin alpha8beta1 in fetal lung morphogenesis and injury. Dev Biol. 2009;335(2):407–17.19769957 10.1016/j.ydbio.2009.09.021
Benjamin JT Epithelial-derived inflammation disrupts Elastin Assembly and alters Saccular Stage Lung Development Am J Pathol 2016 186 7 1786 800 10.1016/j.ajpath.2016.02.016 27181406
Benjamin JT, et al. Epithelial-derived inflammation disrupts Elastin Assembly and alters Saccular Stage Lung Development. Am J Pathol. 2016;186(7):1786–800.27181406 10.1016/j.ajpath.2016.02.016
Brosius Lutz A Al-Nasiry S Kramer BW Mueller M Understanding host-Pathogen interactions in Acute Chorioamnionitis through the Use of Animal models Front Cell Infect Microbiol 2021 11 709309 10.3389/fcimb.2021.709309 34386434
Brosius Lutz A, Al-Nasiry S, Kramer BW, Mueller M. Understanding host-Pathogen interactions in Acute Chorioamnionitis through the Use of Animal models. Front Cell Infect Microbiol. 2021;11:709309.34386434 10.3389/fcimb.2021.709309
Cao L Wang J Tseu I Luo D Post M Maternal exposure to endotoxin delays alveolarization during postnatal rat lung development Am J Physiol Lung Cell Mol Physiol 2009 296 5 L726 37 10.1152/ajplung.90405.2008 19218354
Cao L, Wang J, Tseu I, Luo D, Post M. Maternal exposure to endotoxin delays alveolarization during postnatal rat lung development. Am J Physiol Lung Cell Mol Physiol. 2009;296(5):L726–37.19218354 10.1152/ajplung.90405.2008
Cappelletti M Presicce P Kallapur SG Immunobiology of Acute Chorioamnionitis Front Immunol 2020 11 649 10.3389/fimmu.2020.00649 32373122
Cappelletti M, Presicce P, Kallapur SG. Immunobiology of Acute Chorioamnionitis. Front Immunol. 2020;11:649.32373122 10.3389/fimmu.2020.00649
Castro EC Parks WT Galambos C The ontogeny of human pulmonary angiotensin-converting enzyme and its aberrant expression may contribute to the pathobiology of bronchopulmonary dysplasia (BPD) Pediatr Pulmonol 2014 49 10 985 90 10.1002/ppul.22911 24574430
Castro EC, Parks WT, Galambos C. The ontogeny of human pulmonary angiotensin-converting enzyme and its aberrant expression may contribute to the pathobiology of bronchopulmonary dysplasia (BPD). Pediatr Pulmonol. 2014;49(10):985–90.24574430 10.1002/ppul.22911
Chanda D Otoupalova E Smith SR Volckaert T De Langhe SP Thannickal VJ Developmental pathways in the pathogenesis of lung fibrosis Mol Aspects Med 2019 65 56 69 10.1016/j.mam.2018.08.004 30130563
Chanda D, Otoupalova E, Smith SR, Volckaert T, De Langhe SP, Thannickal VJ. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56–69.30130563 10.1016/j.mam.2018.08.004
Cheah FC Presicce P Tan TL Carey BC Kallapur SG Studying the effects of Granulocyte-Macrophage colony-stimulating factor on fetal lung macrophages during the Perinatal Period using the mouse model Front Pediatr 2021 9 614209 10.3389/fped.2021.614209 33777863
Cheah FC, Presicce P, Tan TL, Carey BC, Kallapur SG. Studying the effects of Granulocyte-Macrophage colony-stimulating factor on fetal lung macrophages during the Perinatal Period using the mouse model. Front Pediatr. 2021b;9:614209.33777863 10.3389/fped.2021.614209
Chen S CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol 2011 300 3 L330 40 10.1152/ajplung.00270.2010 21239535
Chen S, et al. CTGF disrupts alveolarization and induces pulmonary hypertension in neonatal mice: implication in the pathogenesis of severe bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2011;300(3):L330–40.21239535 10.1152/ajplung.00270.2010
Chen Z Xie X Jiang N Li J Shen L Zhang Y CCR5 signaling promotes lipopolysaccharide-induced macrophage recruitment and alveolar developmental arrest Cell Death Dis 2021 12 2 184 10.1038/s41419-021-03464-7 33589608
Chen Z, Xie X, Jiang N, Li J, Shen L, Zhang Y. CCR5 signaling promotes lipopolysaccharide-induced macrophage recruitment and alveolar developmental arrest. Cell Death Dis. 2021;12(2):184.33589608 10.1038/s41419-021-03464-7
Cheong JLY Doyle LW An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia Semin Perinatol 2018 42 7 478 84 10.1053/j.semperi.2018.09.013 30401478
Cheong JLY, Doyle LW. An update on pulmonary and neurodevelopmental outcomes of bronchopulmonary dysplasia. Semin Perinatol. 2018;42(7):478–84.30401478 10.1053/j.semperi.2018.09.013
Choi CW Lee J Oh JY Lee SH Lee HJ Kim BI Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats Pediatr Res 2016 79 2 287 94 10.1038/pr.2015.224 26551413
Choi CW, Lee J, Oh JY, Lee SH, Lee HJ, Kim BI. Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats. Pediatr Res. 2016;79(2):287–94.26551413 10.1038/pr.2015.224
Chou HC Li YT Chen CM Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia Am J Transl Res 2016 8 2 342 53 27158330
Chou HC, Li YT, Chen CM. Human mesenchymal stem cells attenuate experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Am J Transl Res. 2016;8(2):342–53.27158330
Collins JJ Antenatal glucocorticoids counteract LPS changes in TGF-β pathway and caveolin-1 in ovine fetal lung Am J Physiol Lung Cell Mol Physiol 2013 304 6 L438 44 10.1152/ajplung.00251.2012 23333802
Collins JJ, et al. Antenatal glucocorticoids counteract LPS changes in TGF-β pathway and caveolin-1 in ovine fetal lung. Am J Physiol Lung Cell Mol Physiol. 2013;304(6):L438–44.23333802 10.1152/ajplung.00251.2012
Conde-Agudelo A Romero R Jung EJ Garcia Sánchez ÁJ Management of clinical chorioamnionitis: an evidence-based approach Am J Obstet Gynecol 2020 223 6 848 69 10.1016/j.ajog.2020.09.044 33007269
Conde-Agudelo A, Romero R, Jung EJ, Garcia Sánchez ÁJ. Management of clinical chorioamnionitis: an evidence-based approach. Am J Obstet Gynecol. 2020;223(6):848–69.33007269 10.1016/j.ajog.2020.09.044
Costa C Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD Eur Respir J 2016 47 4 1093 102 10.1183/13993003.01642-2015 26965295
Costa C, et al. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. Eur Respir J. 2016;47(4):1093–102.26965295 10.1183/13993003.01642-2015
Costa S et al. Effect of acute histologic chorioamnionitis on bronchopulmonary dysplasia and mortality rate among extremely low gestational age neonates: a retrospective case-control study. Int J Gynaecol Obstet. 2023. Epub ahead of print.
Cui TX CCR2 mediates chronic LPS-Induced Pulmonary inflammation and hypoalveolarization in a murine model of Bronchopulmonary Dysplasia Front Immunol 2020 11 579628 10.3389/fimmu.2020.579628 33117383
Cui TX, et al. CCR2 mediates chronic LPS-Induced Pulmonary inflammation and hypoalveolarization in a murine model of Bronchopulmonary Dysplasia. Front Immunol. 2020;11:579628.33117383 10.3389/fimmu.2020.579628
Dankhara N Holla I Ramarao S Kalikkot Thekkeveedu R Bronchopulmonary dysplasia: Pathogenesis and pathophysiology J Clin Med 2023 12 13 4207 10.3390/jcm12134207 37445242
Dankhara N, Holla I, Ramarao S, Kalikkot Thekkeveedu R. Bronchopulmonary dysplasia: Pathogenesis and pathophysiology. J Clin Med. 2023;12(13):4207.37445242 10.3390/jcm12134207
Davidson LM Berkelhamer SK Bronchopulmonary dysplasia: chronic lung disease of Infancy and Long-Term Pulmonary outcomes J Clin Med 2017 6 1 4 10.3390/jcm6010004 28067830
Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of Infancy and Long-Term Pulmonary outcomes. J Clin Med. 2017;6(1):4.28067830 10.3390/jcm6010004
Day CL Ryan RM Bronchopulmonary dysplasia: new becomes old again! Pediatr Res 2017 81 1–2 210 3 10.1038/pr.2016.201 27682969
Day CL, Ryan RM. Bronchopulmonary dysplasia: new becomes old again! Pediatr Res. 2017;81(1–2):210–3.27682969 10.1038/pr.2016.201
De Paepe ME Hanley LC Lacourse Z Pasquariello T Mao Q Pulmonary dendritic cells in lungs of preterm infants: neglected participants in bronchopulmonary dysplasia? Pediatr Dev Pathol 2011 14 1 20 7 10.2350/09-09-0709-OA.1 20050784
De Paepe ME, Hanley LC, Lacourse Z, Pasquariello T, Mao Q. Pulmonary dendritic cells in lungs of preterm infants: neglected participants in bronchopulmonary dysplasia? Pediatr Dev Pathol. 2011;14(1):20–7.20050784 10.2350/09-09-0709-OA.1
Dessardo NS Chorioamnionitis and chronic lung disease of prematurity: a path analysis of causality Am J Perinatol 2012 29 2 133 40 10.1055/s-0031-1295654 22147641
Dessardo NS, et al. Chorioamnionitis and chronic lung disease of prematurity: a path analysis of causality. Am J Perinatol. 2012;29(2):133–40.22147641 10.1055/s-0031-1295654
Duijts L European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia Eur Respir J 2020 55 1 1900788 10.1183/13993003.00788-2019 31558663
Duijts L, et al. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. Eur Respir J. 2020;55(1):1900788.31558663 10.1183/13993003.00788-2019
Fiaturi N Russo JW Nielsen HC Castellot JJ Jr CCN5 in alveolar epithelial proliferation and differentiation during neonatal lung oxygen injury J Cell Commun Signal 2018 12 1 217 29 10.1007/s12079-017-0443-1 29349730
Fiaturi N, Russo JW, Nielsen HC, Castellot JJ Jr. CCN5 in alveolar epithelial proliferation and differentiation during neonatal lung oxygen injury. J Cell Commun Signal. 2018;12(1):217–29.29349730 10.1007/s12079-017-0443-1
Francis F Fetal inflammatory response syndrome (FIRS) and outcome of preterm neonates - a prospective analytical study J Matern Fetal Neonatal Med 2019 32 3 488 92 10.1080/14767058.2017.1384458 28942689
Francis F, et al. Fetal inflammatory response syndrome (FIRS) and outcome of preterm neonates - a prospective analytical study. J Matern Fetal Neonatal Med. 2019;32(3):488–92.28942689 10.1080/14767058.2017.1384458
Fukunaga S MMP-9 and TIMP-1 in the cord blood of premature infants developing BPD Pediatr Pulmonol 2009 44 3 267 72 10.1002/ppul.20993 19205055
Fukunaga S, et al. MMP-9 and TIMP-1 in the cord blood of premature infants developing BPD. Pediatr Pulmonol. 2009;44(3):267–72.19205055 10.1002/ppul.20993
Ge H Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants Pediatr Pulmonol 2022 57 4 1015 21 10.1002/ppul.25813 34989171
Ge H, et al. Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants. Pediatr Pulmonol. 2022;57(4):1015–21.34989171 10.1002/ppul.25813
Gisslen T Repeated exposure to intra-amniotic LPS partially protects against adverse effects of intravenous LPS in preterm lambs Innate Immun 2014 20 2 214 24 10.1177/1753425913488430 23751819
Gisslen T, et al. Repeated exposure to intra-amniotic LPS partially protects against adverse effects of intravenous LPS in preterm lambs. Innate Immun. 2014;20(2):214–24.23751819 10.1177/1753425913488430
Goldenberg RL The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants Am J Obstet Gynecol 2008 198 1 e431 5 10.1016/j.ajog.2007.07.033
Goldenberg RL, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol. 2008;198(1):e431–5.10.1016/j.ajog.2007.07.033
Gomez R Romero R Ghezzi F Yoon BH Mazor M Berry SM The fetal inflammatory response syndrome Am J Obstet Gynecol 1998 179 1 194 202 10.1016/S0002-9378(98)70272-8 9704787
Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. Am J Obstet Gynecol. 1998;179(1):194–202.9704787 10.1016/S0002-9378(98)70272-8
Gussenhoven R The paradoxical effects of Chronic Intra-amniotic Ureaplasma parvum exposure on ovine fetal Brain Development Dev Neurosci 2017 39 6 472 86 10.1159/000479021 28848098
Gussenhoven R, et al. The paradoxical effects of Chronic Intra-amniotic Ureaplasma parvum exposure on ovine fetal Brain Development. Dev Neurosci. 2017;39(6):472–86.28848098 10.1159/000479021
Hanita T Potential role of prenatal inflammation in the impairment of Lung Development following mechanical ventilation of Preterm lambs Reprod Sci 2017 24 3 478 87 10.1177/1933719116660846 27481923
Hanita T, et al. Potential role of prenatal inflammation in the impairment of Lung Development following mechanical ventilation of Preterm lambs. Reprod Sci. 2017;24(3):478–87.27481923 10.1177/1933719116660846
Hartling L Liang Y Lacaze-Masmonteil T Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis Arch Dis Child Fetal Neonatal Ed 2012 97 1 F8 17 10.1136/adc.2010.210187 21697236
Hartling L, Liang Y, Lacaze-Masmonteil T. Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2012;97(1):F8–17.21697236 10.1136/adc.2010.210187
Heydarian M Schulz C Stoeger T Hilgendorff A Association of immune cell recruitment and BPD development Mol Cell Pediatr 2022 9 1 16 10.1186/s40348-022-00148-w 35917002
Heydarian M, Schulz C, Stoeger T, Hilgendorff A. Association of immune cell recruitment and BPD development. Mol Cell Pediatr. 2022;9(1):16.35917002 10.1186/s40348-022-00148-w
Heymans C Chronic intra-uterine Ureaplasma parvum infection induces Injury of the enteric nervous system in ovine fetuses Front Immunol 2020 11 189 10.3389/fimmu.2020.00189 32256485
Heymans C, et al. Chronic intra-uterine Ureaplasma parvum infection induces Injury of the enteric nervous system in ovine fetuses. Front Immunol. 2020;11:189.32256485 10.3389/fimmu.2020.00189
Higgins RD Bronchopulmonary dysplasia: executive summary of a workshop J Pediatr 2018 197 300 8 10.1016/j.jpeds.2018.01.043 29551318
Higgins RD, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr. 2018;197:300–8.29551318 10.1016/j.jpeds.2018.01.043
Hillman NH Gisslen T Polglase GR Kallapur SG Jobe AH Ventilation-induced increases in EGFR ligand mRNA are not altered by intra-amniotic LPS or ureaplasma in preterm lambs PLoS ONE 2014 9 4 e96087 10.1371/journal.pone.0096087 24788984
Hillman NH, Gisslen T, Polglase GR, Kallapur SG, Jobe AH. Ventilation-induced increases in EGFR ligand mRNA are not altered by intra-amniotic LPS or ureaplasma in preterm lambs. PLoS ONE. 2014;9(4):e96087.24788984 10.1371/journal.pone.0096087
Hirani D Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia Eur Respir J 2022 59 2 2002248 10.1183/13993003.02248-2020 34446466
Hirani D, et al. Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. Eur Respir J. 2022;59(2):2002248.34446466 10.1183/13993003.02248-2020
Hirsch K Perinatal hypoxia-inducible factor stabilization preserves lung alveolar and vascular growth in experimental bronchopulmonary dysplasia Am J Respir Crit Care Med 2020 202 8 1146 58 10.1164/rccm.202003-0601OC 32551816
Hirsch K, et al. Perinatal hypoxia-inducible factor stabilization preserves lung alveolar and vascular growth in experimental bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2020;202(8):1146–58.32551816 10.1164/rccm.202003-0601OC
Hwang JS Rehan VK Recent advances in Bronchopulmonary Dysplasia: pathophysiology, Prevention, and treatment Lung 2018 196 2 129 38 10.1007/s00408-018-0084-z 29374791
Hwang JS, Rehan VK. Recent advances in Bronchopulmonary Dysplasia: pathophysiology, Prevention, and treatment. Lung. 2018;196(2):129–38.29374791 10.1007/s00408-018-0084-z
Jackson CM A potent myeloid response is rapidly activated in the lungs of premature Rhesus macaques exposed to intra-uterine inflammation Mucosal Immunol 2022 15 4 730 44 10.1038/s41385-022-00495-x 35314757
Jackson CM, et al. A potent myeloid response is rapidly activated in the lungs of premature Rhesus macaques exposed to intra-uterine inflammation. Mucosal Immunol. 2022;15(4):730–44.35314757 10.1038/s41385-022-00495-x
Jain VG Willis KA Jobe A Ambalavanan N Chorioamnionitis and neonatal outcomes Pediatr Res 2022 91 2 289 96 10.1038/s41390-021-01633-0 34211129
Jain VG, Willis KA, Jobe A, Ambalavanan N. Chorioamnionitis and neonatal outcomes. Pediatr Res. 2022;91(2):289–96.34211129 10.1038/s41390-021-01633-0
Jensen EA Edwards EM Greenberg LT Soll RF Ehret DEY Horbar JD Severity of Bronchopulmonary Dysplasia among very Preterm infants in the United States Pediatrics 2021 148 1 e2020030007 10.1542/peds.2020-030007 34078747
Jensen EA, Edwards EM, Greenberg LT, Soll RF, Ehret DEY, Horbar JD. Severity of Bronchopulmonary Dysplasia among very Preterm infants in the United States. Pediatrics. 2021;148(1):e2020030007.34078747 10.1542/peds.2020-030007
Jin R IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia Cell Death Discov 2020 6 33 10.1038/s41420-020-0267-2 32377396
Jin R, et al. IL-33-induced neutrophil extracellular traps degrade fibronectin in a murine model of bronchopulmonary dysplasia. Cell Death Discov. 2020;6:33.32377396 10.1038/s41420-020-0267-2
Jobe AH Goldenberg RL Antenatal corticosteroids: an assessment of anticipated benefits and potential risks Am J Obstet Gynecol 2018 219 1 62 74 10.1016/j.ajog.2018.04.007 29630886
Jobe AH, Goldenberg RL. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2018;219(1):62–74.29630886 10.1016/j.ajog.2018.04.007
Jung E The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diagnosis, and obstetrical implications Semin Fetal Neonatal Med 2020 25 4 101146 10.1016/j.siny.2020.101146 33164775
Jung E, et al. The fetal inflammatory response syndrome: the origins of a concept, pathophysiology, diagnosis, and obstetrical implications. Semin Fetal Neonatal Med. 2020;25(4):101146.33164775 10.1016/j.siny.2020.101146
Kallapur SG Chronic endotoxin exposure does not cause sustained structural abnormalities in the fetal sheep lungs Am J Physiol Lung Cell Mol Physiol 2005 288 5 L966 74 10.1152/ajplung.00389.2004 15640284
Kallapur SG, et al. Chronic endotoxin exposure does not cause sustained structural abnormalities in the fetal sheep lungs. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L966–74.15640284 10.1152/ajplung.00389.2004
Kallapur SG Pulmonary and systemic endotoxin tolerance in preterm fetal sheep exposed to chorioamnionitis J Immunol 2007 179 12 8491 9 10.4049/jimmunol.179.12.8491 18056396
Kallapur SG, et al. Pulmonary and systemic endotoxin tolerance in preterm fetal sheep exposed to chorioamnionitis. J Immunol. 2007;179(12):8491–9.18056396 10.4049/jimmunol.179.12.8491
Kallapur SG IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide Am J Respir Crit Care Med 2009 179 10 955 61 10.1164/rccm.200811-1728OC 19234101
Kallapur SG, et al. IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide. Am J Respir Crit Care Med. 2009;179(10):955–61.19234101 10.1164/rccm.200811-1728OC
Kallapur SG Presicce P Rueda CM Jobe AH Chougnet CA Fetal immune response to chorioamnionitis Semin Reprod Med 2014 32 1 56 67 10.1055/s-0033-1361823 24390922
Kallapur SG, Presicce P, Rueda CM, Jobe AH, Chougnet CA. Fetal immune response to chorioamnionitis. Semin Reprod Med. 2014;32(1):56–67.24390922 10.1055/s-0033-1361823
Kalymbetova TV Resident alveolar macrophages are master regulators of arrested alveolarization in experimental bronchopulmonary dysplasia J Pathol 2018 245 2 153 59 10.1002/path.5076 29574785
Kalymbetova TV, et al. Resident alveolar macrophages are master regulators of arrested alveolarization in experimental bronchopulmonary dysplasia. J Pathol. 2018;245(2):153–59.29574785 10.1002/path.5076
Khong TY Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement Arch Pathol Lab Med 2016 140 7 698 713 10.5858/arpa.2015-0225-CC 27223167
Khong TY, et al. Sampling and definitions of placental lesions: Amsterdam Placental Workshop Group Consensus Statement. Arch Pathol Lab Med. 2016;140(7):698–713.27223167 10.5858/arpa.2015-0225-CC
Kim CJ Romero R Chaemsaithong P Chaiyasit N Yoon BH Kim YM Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance Am J Obstet Gynecol 2015 213 4 Suppl S29 52 10.1016/j.ajog.2015.08.040 26428501
Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol. 2015a;213(4 Suppl):S29–52.26428501 10.1016/j.ajog.2015.08.040
Kim SY Neonatal morbidities Associated with histologic Chorioamnionitis defined based on the site and extent of inflammation in very low Birth Weight infants J Korean Med Sci 2015 30 10 1476 82 10.3346/jkms.2015.30.10.1476 26425046
Kim SY, et al. Neonatal morbidities Associated with histologic Chorioamnionitis defined based on the site and extent of inflammation in very low Birth Weight infants. J Korean Med Sci. 2015b;30(10):1476–82.26425046 10.3346/jkms.2015.30.10.1476
Kovács K The histologic fetal inflammatory response and neonatal outcomes: systematic review and meta-analysis Am J Obstet Gynecol 2023 S0002–9378 23 02025 2
Kovács K, et al. The histologic fetal inflammatory response and neonatal outcomes: systematic review and meta-analysis. Am J Obstet Gynecol. 2023;S0002–9378(23):02025–2.
Kramer BW Ikegami M Moss TJ Nitsos I Newnham JP Jobe AH Endotoxin-induced chorioamnionitis modulates innate immunity of monocytes in preterm sheep Am J Respir Crit Care Med 2005 171 1 73 7 10.1164/rccm.200406-745OC 15466254
Kramer BW, Ikegami M, Moss TJ, Nitsos I, Newnham JP, Jobe AH. Endotoxin-induced chorioamnionitis modulates innate immunity of monocytes in preterm sheep. Am J Respir Crit Care Med. 2005;171(1):73–7.15466254 10.1164/rccm.200406-745OC
Kramer EL Perinatal increases in TGF-{alpha} disrupt the saccular phase of lung morphogenesis and cause remodeling: microarray analysis Am J Physiol Lung Cell Mol Physiol 2007 293 2 L314 27 10.1152/ajplung.00354.2006 17468132
Kramer EL, et al. Perinatal increases in TGF-{alpha} disrupt the saccular phase of lung morphogenesis and cause remodeling: microarray analysis. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L314–27.17468132 10.1152/ajplung.00354.2006
Kramer BW Kallapur S Newnham J Jobe AH Prenatal inflammation and lung development Semin Fetal Neonatal Med 2009 14 1 2 7 10.1016/j.siny.2008.08.011 18845493
Kramer BW, Kallapur S, Newnham J, Jobe AH. Prenatal inflammation and lung development. Semin Fetal Neonatal Med. 2009;14(1):2–7.18845493 10.1016/j.siny.2008.08.011
Kunzmann S Speer CP Jobe AH Kramer BW Antenatal inflammation induced TGF-beta1 but suppressed CTGF in preterm lungs Am J Physiol Lung Cell Mol Physiol 2007 292 1 L223 31 10.1152/ajplung.00159.2006 16936247
Kunzmann S, Speer CP, Jobe AH, Kramer BW. Antenatal inflammation induced TGF-beta1 but suppressed CTGF in preterm lungs. Am J Physiol Lung Cell Mol Physiol. 2007;292(1):L223–31.16936247 10.1152/ajplung.00159.2006
Kunzmann S Hütten M Ottensmeier B Kramer BW Fehrholz M A20 is increased in fetal lung in a Sheep LPS model of Chorioamnionitis Oxid Med Cell Longev 2022 2022 6421419 10.1155/2022/6421419 35096271
Kunzmann S, Hütten M, Ottensmeier B, Kramer BW, Fehrholz M. A20 is increased in fetal lung in a Sheep LPS model of Chorioamnionitis. Oxid Med Cell Longev. 2022;2022:6421419.35096271 10.1155/2022/6421419
Kuypers E Intra-amniotic LPS and antenatal betamethasone: inflammation and maturation in preterm lamb lungs Am J Physiol Lung Cell Mol Physiol 2012 302 4 L380 9 10.1152/ajplung.00338.2011 22160306
Kuypers E, et al. Intra-amniotic LPS and antenatal betamethasone: inflammation and maturation in preterm lamb lungs. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L380–9.22160306 10.1152/ajplung.00338.2011
Laddha AP Kulkarni YA VEGF and FGF-2: promising targets for the treatment of respiratory disorders Respir Med 2019 156 33 46 10.1016/j.rmed.2019.08.003 31421589
Laddha AP, Kulkarni YA. VEGF and FGF-2: promising targets for the treatment of respiratory disorders. Respir Med. 2019;156:33–46.31421589 10.1016/j.rmed.2019.08.003
Lazarus A Keshet E Vascular endothelial growth factor and vascular homeostasis Proc Am Thorac Soc 2011 8 6 508 11 10.1513/pats.201102-021MW 22052928
Lazarus A, Keshet E. Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc. 2011;8(6):508–11.22052928 10.1513/pats.201102-021MW
Le Cras TD Markham NE Tuder RM Voelkel NF Abman SH Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure Am J Physiol Lung Cell Mol Physiol 2002 283 3 L555 62 10.1152/ajplung.00408.2001 12169575
Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L555–62.12169575 10.1152/ajplung.00408.2001
Lee C Low levels of tissue inhibitor of metalloproteinase-2 at birth may be associated with subsequent development of bronchopulmonary dysplasia in preterm infants Korean J Pediatr 2015 58 11 415 20 10.3345/kjp.2015.58.11.415 26692876
Lee C, et al. Low levels of tissue inhibitor of metalloproteinase-2 at birth may be associated with subsequent development of bronchopulmonary dysplasia in preterm infants. Korean J Pediatr. 2015a;58(11):415–20.26692876 10.3345/kjp.2015.58.11.415
Lee Y, et al. Is there a stepwise increase in neonatal morbidities according to histological stage (or grade) of acute chorioamnionitis and funisitis?: effect of gestational age at delivery. J Perinat Med. 2015b;43(2):259–67.
Li H, Yuan X, Tang J, Zhang Y. Lipopolysaccharide disrupts the directional persistence of alveolar myofibroblast migration through EGF receptor. Am J Physiol Lung Cell Mol Physiol. 2012;302(6):L569–79.
Li J Gong X 14-3-3β is necessary in the regulation of polarization and directional migration of alveolar myofibroblasts by lipopolysaccharide Exp Lung Res 2020 46 1–2 1 10 10.1080/01902148.2019.1711464 31920140
Li J, Gong X. 14-3-3β is necessary in the regulation of polarization and directional migration of alveolar myofibroblasts by lipopolysaccharide. Exp Lung Res. 2020;46(1–2):1–10.31920140 10.1080/01902148.2019.1711464
Li J Csk/Src/EGFR signaling regulates migration of myofibroblasts and alveolarization Am J Physiol Lung Cell Mol Physiol 2016 310 6 L562 71 10.1152/ajplung.00162.2015 26773066
Li J, et al. Csk/Src/EGFR signaling regulates migration of myofibroblasts and alveolarization. Am J Physiol Lung Cell Mol Physiol. 2016;310(6):L562–71.26773066 10.1152/ajplung.00162.2015
Liu C Chen Z Li W Huang L Zhang Y Vitamin D enhances Alveolar Development in Antenatal Lipopolysaccharide-treated rats through the suppression of Interferon-γ production Front Immunol 2018 8 1923 10.3389/fimmu.2017.01923 29354129
Liu C, Chen Z, Li W, Huang L, Zhang Y. Vitamin D enhances Alveolar Development in Antenatal Lipopolysaccharide-treated rats through the suppression of Interferon-γ production. Front Immunol. 2018;8:1923.29354129 10.3389/fimmu.2017.01923
Liu G Therapeutic targets in lung tissue remodelling and fibrosis Pharmacol Ther 2021 225 107839 10.1016/j.pharmthera.2021.107839 33774068
Liu G, et al. Therapeutic targets in lung tissue remodelling and fibrosis. Pharmacol Ther. 2021;225:107839.33774068 10.1016/j.pharmthera.2021.107839
Lui K Trends in outcomes for neonates born very Preterm and very low Birth Weight in 11 high-income countries J Pediatr 2019 215 32 e4014 10.1016/j.jpeds.2019.08.020 31587861
Lui K, et al. Trends in outcomes for neonates born very Preterm and very low Birth Weight in 11 high-income countries. J Pediatr. 2019;215:32–e4014.31587861 10.1016/j.jpeds.2019.08.020
Mandell E Seedorf G Gien J Abman SH Vitamin D treatment improves survival and infant lung structure after intra-amniotic endotoxin exposure in rats: potential role for the prevention of bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol 2014 306 5 L420 8 10.1152/ajplung.00344.2013 24414254
Mandell E, Seedorf G, Gien J, Abman SH. Vitamin D treatment improves survival and infant lung structure after intra-amniotic endotoxin exposure in rats: potential role for the prevention of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2014;306(5):L420–8.24414254 10.1152/ajplung.00344.2013
Mandell E Seedorf GJ Ryan S Gien J Cramer SD Abman SH Antenatal endotoxin disrupts lung vitamin D receptor and 25-hydroxyvitamin D 1α-hydroxylase expression in the developing rat Am J Physiol Lung Cell Mol Physiol 2015 309 9 L1018 26 10.1152/ajplung.00253.2015 26342089
Mandell E, Seedorf GJ, Ryan S, Gien J, Cramer SD, Abman SH. Antenatal endotoxin disrupts lung vitamin D receptor and 25-hydroxyvitamin D 1α-hydroxylase expression in the developing rat. Am J Physiol Lung Cell Mol Physiol. 2015;309(9):L1018–26.26342089 10.1152/ajplung.00253.2015
Mandell EW Antenatal Endotoxin impairs lung mechanics and increases sensitivity to Ventilator-Induced Lung Injury in Newborn Rat pups Front Physiol 2021 11 614283 10.3389/fphys.2020.614283 33519519
Mandell EW, et al. Antenatal Endotoxin impairs lung mechanics and increases sensitivity to Ventilator-Induced Lung Injury in Newborn Rat pups. Front Physiol. 2021;11:614283.33519519 10.3389/fphys.2020.614283
Marega M El-Merhie N Gökyildirim MY Orth V Bellusci S Chao CM Stem/Progenitor cells and related therapy in Bronchopulmonary Dysplasia Int J Mol Sci 2023 24 13 11229 10.3390/ijms241311229 37446407
Marega M, El-Merhie N, Gökyildirim MY, Orth V, Bellusci S, Chao CM. Stem/Progenitor cells and related therapy in Bronchopulmonary Dysplasia. Int J Mol Sci. 2023;24(13):11229.37446407 10.3390/ijms241311229
Martinelli P Sarno L Maruotti GM Paludetto R Chorioamnionitis and prematurity: a critical review J Matern Fetal Neonatal Med 2012 25 Suppl 4 29 31 22958008
Martinelli P, Sarno L, Maruotti GM, Paludetto R. Chorioamnionitis and prematurity: a critical review. J Matern Fetal Neonatal Med. 2012;25(Suppl 4):29–31.22958008
Miller JD Benjamin JT Kelly DR Frank DB Prince LS Chorioamnionitis stimulates angiogenesis in saccular stage fetal lungs via CC chemokines Am J Physiol Lung Cell Mol Physiol 2010 298 5 L637 45 10.1152/ajplung.00414.2009 20172951
Miller JD, Benjamin JT, Kelly DR, Frank DB, Prince LS. Chorioamnionitis stimulates angiogenesis in saccular stage fetal lungs via CC chemokines. Am J Physiol Lung Cell Mol Physiol. 2010;298(5):L637–45.20172951 10.1152/ajplung.00414.2009
Minton K Extracellular matrix: preconditioning the ECM for fibrosis Nat Rev Mol Cell Biol 2014 15 12 766 7 10.1038/nrm3906 25387397
Minton K. Extracellular matrix: preconditioning the ECM for fibrosis. Nat Rev Mol Cell Biol. 2014;15(12):766–7.25387397 10.1038/nrm3906
Mižíková I Morty RE The Extracellular Matrix in Bronchopulmonary Dysplasia: target and source Front Med (Lausanne) 2015 2 91 26779482
Mižíková I, Morty RE. The Extracellular Matrix in Bronchopulmonary Dysplasia: target and source. Front Med (Lausanne). 2015;2:91.26779482
Mižíková I Collagen and elastin cross-linking is altered during aberrant late lung development associated with hyperoxia Am J Physiol Lung Cell Mol Physiol 2015 308 11 L1145 58 10.1152/ajplung.00039.2015 25840994
Mižíková I, et al. Collagen and elastin cross-linking is altered during aberrant late lung development associated with hyperoxia. Am J Physiol Lung Cell Mol Physiol. 2015;308(11):L1145–58.25840994 10.1152/ajplung.00039.2015
Muraskas J Astrug L Amin S FIRS: neonatal considerations Semin Fetal Neonatal Med 2020 25 4 101142 10.1016/j.siny.2020.101142 32912755
Muraskas J, Astrug L, Amin S. FIRS: neonatal considerations. Semin Fetal Neonatal Med. 2020;25(4):101142.32912755 10.1016/j.siny.2020.101142
Murthy V Kennea NL Antenatal infection/inflammation and fetal tissue injury Best Pract Res Clin Obstet Gynaecol 2007 21 3 479 89 10.1016/j.bpobgyn.2007.01.010 17363332
Murthy V, Kennea NL. Antenatal infection/inflammation and fetal tissue injury. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):479–89.17363332 10.1016/j.bpobgyn.2007.01.010
Ni W Lin N He H Zhu J Zhang Y Lipopolysaccharide induces up-regulation of TGF-α through HDAC2 in a rat model of bronchopulmonary dysplasia PLoS ONE 2014 9 3 e91083 10.1371/journal.pone.0091083 24595367
Ni W, Lin N, He H, Zhu J, Zhang Y. Lipopolysaccharide induces up-regulation of TGF-α through HDAC2 in a rat model of bronchopulmonary dysplasia. PLoS ONE. 2014;9(3):e91083.24595367 10.1371/journal.pone.0091083
Ninan K Liyanage SK Murphy KE Asztalos EV McDonald SD Evaluation of Long-Term outcomes Associated with Preterm exposure to Antenatal corticosteroids: a systematic review and Meta-analysis JAMA Pediatr 2022 176 6 e220483 10.1001/jamapediatrics.2022.0483 35404395
Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-Term outcomes Associated with Preterm exposure to Antenatal corticosteroids: a systematic review and Meta-analysis. JAMA Pediatr. 2022;176(6):e220483.35404395 10.1001/jamapediatrics.2022.0483
Nold MF Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia Proc Natl Acad Sci U S A 2013 110 35 14384 9 10.1073/pnas.1306859110 23946428
Nold MF, et al. Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. Proc Natl Acad Sci U S A. 2013;110(35):14384–9.23946428 10.1073/pnas.1306859110
Nomiyama M Contribution of fetal inflammatory response syndrome (FIRS) with or without maternal-fetal inflammation in the placenta to increased risk of respiratory and other complications in Preterm neonates Biomedicines 2023 11 2 611 10.3390/biomedicines11020611 36831147
Nomiyama M, et al. Contribution of fetal inflammatory response syndrome (FIRS) with or without maternal-fetal inflammation in the placenta to increased risk of respiratory and other complications in Preterm neonates. Biomedicines. 2023;11(2):611.36831147 10.3390/biomedicines11020611
Northway WH Jr Rosan RC Porter DY Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia N Engl J Med 1967 276 7 357 68 10.1056/NEJM196702162760701 5334613
Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357–68.5334613 10.1056/NEJM196702162760701
O’Reilly M Thébaud B Animal models of bronchopulmonary dysplasia. The term rat models Am J Physiol Lung Cell Mol Physiol 2014 307 12 L948 58 10.1152/ajplung.00160.2014 25305248
O’Reilly M, Thébaud B. Animal models of bronchopulmonary dysplasia. The term rat models. Am J Physiol Lung Cell Mol Physiol. 2014;307(12):L948–58.25305248 10.1152/ajplung.00160.2014
Pacora P Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome J Matern Fetal Neonatal Med 2002 11 1 18 25 10.1080/jmf.11.1.18.25 12380603
Pacora P, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med. 2002;11(1):18–25.12380603 10.1080/jmf.11.1.18.25
Pan J Effects and molecular mechanisms of intrauterine infection/inflammation on lung development Respir Res 2018 19 1 93 10.1186/s12931-018-0787-y 29747649
Pan J, et al. Effects and molecular mechanisms of intrauterine infection/inflammation on lung development. Respir Res. 2018;19(1):93.29747649 10.1186/s12931-018-0787-y
Pan J Long noncoding RNA signatures in intrauterine infection/inflammation-induced lung injury: an integrative bioinformatics study BMC Pulm Med 2023 23 1 194 10.1186/s12890-023-02505-5 37280583
Pan J, et al. Long noncoding RNA signatures in intrauterine infection/inflammation-induced lung injury: an integrative bioinformatics study. BMC Pulm Med. 2023;23(1):194.37280583 10.1186/s12890-023-02505-5
Park HW Lim G Park YM Chang M Son JS Lee R Association between vitamin D level and bronchopulmonary dysplasia: a systematic review and meta-analysis PLoS ONE 2020 15 7 e0235332 10.1371/journal.pone.0235332 32628705
Park HW, Lim G, Park YM, Chang M, Son JS, Lee R. Association between vitamin D level and bronchopulmonary dysplasia: a systematic review and meta-analysis. PLoS ONE. 2020;15(7):e0235332.32628705 10.1371/journal.pone.0235332
Pérez-Tarazona S Respiratory outcomes of new bronchopulmonary dysplasia in adolescents: a multicenter study Pediatr Pulmonol 2021 56 5 1205 14 10.1002/ppul.25226 33314679
Pérez-Tarazona S, et al. Respiratory outcomes of new bronchopulmonary dysplasia in adolescents: a multicenter study. Pediatr Pulmonol. 2021;56(5):1205–14.33314679 10.1002/ppul.25226
Perniciaro S Early- and late-respiratory outcome in very low Birth Weight with or without intrauterine inflammation Am J Perinatol 2020 37 S02 S76 83 32898888
Perniciaro S, et al. Early- and late-respiratory outcome in very low Birth Weight with or without intrauterine inflammation. Am J Perinatol. 2020;37(S02):S76–83.32898888
Prince LS Dieperink HI Okoh VO Fierro-Perez GA Lallone RL Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung Dev Dyn 2005 233 2 553 61 10.1002/dvdy.20362 15830384
Prince LS, Dieperink HI, Okoh VO, Fierro-Perez GA, Lallone RL. Toll-like receptor signaling inhibits structural development of the distal fetal mouse lung. Dev Dyn. 2005;233(2):553–61.15830384 10.1002/dvdy.20362
Rehan VK A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung Am J Physiol Lung Cell Mol Physiol 2007 293 1 L182 90 10.1152/ajplung.00319.2006 17435078
Rehan VK, et al. A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2007;293(1):L182–90.17435078 10.1152/ajplung.00319.2006
Rippa AL Alpeeva EV Vasiliev AV Vorotelyak EA Alveologenesis: what governs secondary Septa formation Int J Mol Sci 2021 22 22 12107 10.3390/ijms222212107 34829987
Rippa AL, Alpeeva EV, Vasiliev AV, Vorotelyak EA. Alveologenesis: what governs secondary Septa formation. Int J Mol Sci. 2021;22(22):12107.34829987 10.3390/ijms222212107
Roberts D Brown J Medley N Dalziel SR Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth Cochrane Database Syst Rev 2017 3 3 CD004454 28321847
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454.28321847
Ruschkowski BA Thrombospondin-1 plays a major pathogenic role in experimental and human bronchopulmonary dysplasia Am J Respir Crit Care Med 2022 205 6 685 99 10.1164/rccm.202104-1021OC 35021035
Ruschkowski BA, et al. Thrombospondin-1 plays a major pathogenic role in experimental and human bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2022;205(6):685–99.35021035 10.1164/rccm.202104-1021OC
Salimi U Dummula K Tucker MH Dela Cruz CS Sampath V Postnatal Sepsis and bronchopulmonary dysplasia in premature infants: mechanistic insights into New BPD Am J Respir Cell Mol Biol 2022 66 2 137 45 10.1165/rcmb.2021-0353PS 34644520
Salimi U, Dummula K, Tucker MH, Dela Cruz CS, Sampath V. Postnatal Sepsis and bronchopulmonary dysplasia in premature infants: mechanistic insights into New BPD. Am J Respir Cell Mol Biol. 2022;66(2):137–45.34644520 10.1165/rcmb.2021-0353PS
Schmidt AR Ramamoorthy C Bronchopulmonary dysplasia Paediatr Anaesth 2022 32 2 174 80 10.1111/pan.14365 34877749
Schmidt AR, Ramamoorthy C. Bronchopulmonary dysplasia. Paediatr Anaesth. 2022;32(2):174–80.34877749 10.1111/pan.14365
Semenza GL Pharmacologic targeting of Hypoxia-Inducible factors Annu Rev Pharmacol Toxicol 2019 59 379 403 10.1146/annurev-pharmtox-010818-021637 30625281
Semenza GL. Pharmacologic targeting of Hypoxia-Inducible factors. Annu Rev Pharmacol Toxicol. 2019;59:379–403.30625281 10.1146/annurev-pharmtox-010818-021637
Shahzad T Radajewski S Chao CM Bellusci S Ehrhardt H Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development Mol Cell Pediatr 2016 3 1 23 10.1186/s40348-016-0051-9 27357257
Shahzad T, Radajewski S, Chao CM, Bellusci S, Ehrhardt H. Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development. Mol Cell Pediatr. 2016;3(1):23.27357257 10.1186/s40348-016-0051-9
Sibley CH Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes Arthritis Rheum 2012 64 7 2375 86 10.1002/art.34409 22294344
Sibley CH, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64(7):2375–86.22294344 10.1002/art.34409
Somashekar ST, et al. Intra-Amniotic Soluble Endoglin Impairs Lung Development in Neonatal Rats. Am J Respir Cell Mol Biol. 2017;57(4):468–76.
Stouch AN, et al. IL-1β and Inflammasome Activity Link Inflammation to Abnormal Fetal Airway Development. J Immunol. 2016;196(8):3411–20.
Sun T Yu HY Yang M Song YF Fu JH Risk of asthma in preterm infants with bronchopulmonary dysplasia: a systematic review and meta-analysis World J Pediatr 2023 19 6 549 56 10.1007/s12519-023-00701-1 36857022
Sun T, Yu HY, Yang M, Song YF, Fu JH. Risk of asthma in preterm infants with bronchopulmonary dysplasia: a systematic review and meta-analysis. World J Pediatr. 2023;19(6):549–56.36857022 10.1007/s12519-023-00701-1
Syed MA Bhandari V Hyperoxia exacerbates postnatal inflammation-induced lung injury in neonatal BRP-39 null mutant mice promoting the M1 macrophage phenotype Mediators Inflamm 2013 2013 457189 10.1155/2013/457189 24347826
Syed MA, Bhandari V. Hyperoxia exacerbates postnatal inflammation-induced lung injury in neonatal BRP-39 null mutant mice promoting the M1 macrophage phenotype. Mediators Inflamm. 2013;2013:457189.24347826 10.1155/2013/457189
Taglauer E Abman SH Keller RL Recent advances in antenatal factors predisposing to bronchopulmonary dysplasia Semin Perinatol 2018 42 7 413 24 10.1053/j.semperi.2018.09.002 30389227
Taglauer E, Abman SH, Keller RL. Recent advances in antenatal factors predisposing to bronchopulmonary dysplasia. Semin Perinatol. 2018;42(7):413–24.30389227 10.1053/j.semperi.2018.09.002
Tang JR Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin Am J Physiol Lung Cell Mol Physiol 2010 299 6 L735 48 10.1152/ajplung.00153.2010 20709730
Tang JR, et al. Moderate postnatal hyperoxia accelerates lung growth and attenuates pulmonary hypertension in infant rats after exposure to intra-amniotic endotoxin. Am J Physiol Lung Cell Mol Physiol. 2010;299(6):L735–48.20709730 10.1152/ajplung.00153.2010
Tang Q Zhang L Li H Shao Y The fetal inflammation response syndrome and adverse neonatal outcomes: a meta-analysis J Matern Fetal Neonatal Med 2021 34 23 3902 14 10.1080/14767058.2019.1702942 31852288
Tang Q, Zhang L, Li H, Shao Y. The fetal inflammation response syndrome and adverse neonatal outcomes: a meta-analysis. J Matern Fetal Neonatal Med. 2021;34(23):3902–14.31852288 10.1080/14767058.2019.1702942
Thébaud B Bronchopulmonary dysplasia Nat Rev Dis Primers 2019 5 1 78 10.1038/s41572-019-0127-7 31727986
Thébaud B, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers. 2019;5(1):78.31727986 10.1038/s41572-019-0127-7
Ueda K A rat model for arrest of alveolarization induced by antenatal endotoxin administration Pediatr Res 2006 59 3 396 400 10.1203/01.pdr.0000200796.86858.ca 16492978
Ueda K, et al. A rat model for arrest of alveolarization induced by antenatal endotoxin administration. Pediatr Res. 2006;59(3):396–400.16492978 10.1203/01.pdr.0000200796.86858.ca
Villamor-Martinez E Association of Chorioamnionitis with Bronchopulmonary Dysplasia among Preterm infants: a systematic review, Meta-analysis, and Metaregression JAMA Netw Open 2019 2 11 e1914611 10.1001/jamanetworkopen.2019.14611 31693123
Villamor-Martinez E, et al. Association of Chorioamnionitis with Bronchopulmonary Dysplasia among Preterm infants: a systematic review, Meta-analysis, and Metaregression. JAMA Netw Open. 2019;2(11):e1914611.31693123 10.1001/jamanetworkopen.2019.14611
Wallace B Anti-sflt-1 therapy preserves lung alveolar and vascular growth in Antenatal models of Bronchopulmonary Dysplasia Am J Respir Crit Care Med 2018 197 6 776 87 10.1164/rccm.201707-1371OC 29268623
Wallace B, et al. Anti-sflt-1 therapy preserves lung alveolar and vascular growth in Antenatal models of Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2018;197(6):776–87.29268623 10.1164/rccm.201707-1371OC
Widowski H Sequential exposure to Antenatal Microbial triggers attenuates Alveolar Growth and Pulmonary Vascular Development and impacts Pulmonary epithelial Stem/Progenitor cells Front Med (Lausanne) 2021 8 614239 10.3389/fmed.2021.614239 33693012
Widowski H, et al. Sequential exposure to Antenatal Microbial triggers attenuates Alveolar Growth and Pulmonary Vascular Development and impacts Pulmonary epithelial Stem/Progenitor cells. Front Med (Lausanne). 2021;8:614239.33693012 10.3389/fmed.2021.614239
Willems MGM Pulmonary vascular changes in extremely preterm sheep after intra-amniotic exposure to Ureaplasma parvum and lipopolysaccharide PLoS ONE 2017 12 6 e0180114 10.1371/journal.pone.0180114 28666032
Willems MGM, et al. Pulmonary vascular changes in extremely preterm sheep after intra-amniotic exposure to Ureaplasma parvum and lipopolysaccharide. PLoS ONE. 2017;12(6):e0180114.28666032 10.1371/journal.pone.0180114
Willet KE Jobe AH Ikegami M Newnham J Brennan S Sly PD Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs Pediatr Res 2000 48 6 782 8 10.1203/00006450-200012000-00014 11102547
Willet KE, Jobe AH, Ikegami M, Newnham J, Brennan S, Sly PD. Antenatal endotoxin and glucocorticoid effects on lung morphometry in preterm lambs. Pediatr Res. 2000;48(6):782–8.11102547 10.1203/00006450-200012000-00014
Willis GR Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through Macrophage Immunomodulation Am J Respir Crit Care Med 2018 197 1 104 16 10.1164/rccm.201705-0925OC 28853608
Willis GR, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104–16.28853608 10.1164/rccm.201705-0925OC
Wösten-van Asperen RM Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist J Pathol 2011 225 4 618 27 10.1002/path.2987 22009550
Wösten-van Asperen RM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol. 2011;225(4):618–27.22009550 10.1002/path.2987
Wu A Song H Regulation of alveolar type 2 stem/progenitor cells in lung injury and regeneration Acta Biochim Biophys Sin (Shanghai) 2020 52 7 716 22 10.1093/abbs/gmaa052 32445469
Wu A, Song H. Regulation of alveolar type 2 stem/progenitor cells in lung injury and regeneration. Acta Biochim Biophys Sin (Shanghai). 2020;52(7):716–22.32445469 10.1093/abbs/gmaa052
Wu X Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial) Trials 2020 21 1 125 10.1186/s13063-019-3935-x 32005282
Wu X, et al. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (MSC-BPD trial). Trials. 2020;21(1):125.32005282 10.1186/s13063-019-3935-x
Xia H Foxm1 regulates resolution of hyperoxic lung injury in newborns Am J Respir Cell Mol Biol 2015 52 5 611 21 10.1165/rcmb.2014-0091OC 25275225
Xia H, et al. Foxm1 regulates resolution of hyperoxic lung injury in newborns. Am J Respir Cell Mol Biol. 2015;52(5):611–21.25275225 10.1165/rcmb.2014-0091OC
Yan Y Levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are related to cardiopulmonary injury in fetal inflammatory response syndrome Clin (Sao Paulo) 2020 75 e2049 10.6061/clinics/2020/e2049
Yan Y, et al. Levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are related to cardiopulmonary injury in fetal inflammatory response syndrome. Clin (Sao Paulo). 2020;75:e2049.10.6061/clinics/2020/e2049
Yilmaz A Aslan MT İnce Z Vural M Mesenchymal stem cell therapy in a Preterm Infant with Bronchopulmonary Dysplasia Indian J Pediatr 2021 88 12 1262 10.1007/s12098-021-03946-8 34436738
Yilmaz A, Aslan MT, İnce Z, Vural M. Mesenchymal stem cell therapy in a Preterm Infant with Bronchopulmonary Dysplasia. Indian J Pediatr. 2021;88(12):1262.34436738 10.1007/s12098-021-03946-8
Zhang C Cao J Xu M Wu D Li W Chang Y The role of neutrophils in chorioamnionitis Front Immunol 2023 14 1198831 10.3389/fimmu.2023.1198831 37475854
Zhang C, Cao J, Xu M, Wu D, Li W, Chang Y. The role of neutrophils in chorioamnionitis. Front Immunol. 2023a;14:1198831.37475854 10.3389/fimmu.2023.1198831
Zhang S Mulder C Riddle S Song R Yue D Mesenchymal stromal/stem cells and bronchopulmonary dysplasia Front Cell Dev Biol 2023 11 1247339 10.3389/fcell.2023.1247339 37965579
Zhang S, Mulder C, Riddle S, Song R, Yue D. Mesenchymal stromal/stem cells and bronchopulmonary dysplasia. Front Cell Dev Biol. 2023b;11:1247339.37965579 10.3389/fcell.2023.1247339
Zhou Y Extracellular matrix in lung development, homeostasis and disease Matrix Biol 2018 73 77 104 10.1016/j.matbio.2018.03.005 29524630
Zhou Y, et al. Extracellular matrix in lung development, homeostasis and disease. Matrix Biol. 2018;73:77–104.29524630 10.1016/j.matbio.2018.03.005
Zhou O Microvesicles derived from human umbilical cord mesenchymal stem cells enhance alveolar type II cell proliferation and attenuate lung inflammation in a rat model of Bronchopulmonary Dysplasia Stem Cells Int 2022 2022 8465294 10.1155/2022/8465294 35795773
Zhou O, et al. Microvesicles derived from human umbilical cord mesenchymal stem cells enhance alveolar type II cell proliferation and attenuate lung inflammation in a rat model of Bronchopulmonary Dysplasia. Stem Cells Int. 2022;2022:8465294.35795773 10.1155/2022/8465294
Zhu Y Yao HC Lu HY Hao XB Xu SQ IL-33-ST2 pathway regulates AECII transdifferentiation by targeting alveolar macrophage in a bronchopulmonary dysplasia mouse model J Cell Mol Med 2023 27 2 304 8 10.1111/jcmm.17654 36573439
Zhu Y, Yao HC, Lu HY, Hao XB, Xu SQ. IL-33-ST2 pathway regulates AECII transdifferentiation by targeting alveolar macrophage in a bronchopulmonary dysplasia mouse model. J Cell Mol Med. 2023;27(2):304–8.36573439 10.1111/jcmm.17654
